<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Daptomycin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Daptomycin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Daptomycin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11333" href="/d/html/11333.html" rel="external">see "Daptomycin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13009" href="/d/html/13009.html" rel="external">see "Daptomycin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F156919"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cubicin RF;</li>
<li>Cubicin [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866514"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cubicin RF;</li>
<li>Cubicin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F156936"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cyclic Lipopeptide</li></ul></div>
<div class="block doa drugH1Div" id="F156921"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Do not use for the treatment of pneumonia due to inactivation of antimicrobial activity by pulmonary surfactant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15898002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15898002'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric or pathogen-directed therapy for methicillin-resistant Staphylococcus aureus</i>
<i>:</i>
<b>IV:</b> 8 to 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-Lowy.1','lexi-content-ref-32725216','lexi-content-ref-29235661','lexi-content-ref-35146040']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-Lowy.1','lexi-content-ref-32725216','lexi-content-ref-29235661','lexi-content-ref-35146040'])">Ref</a></span>). For persistent or refractory cases or isolates with reduced susceptibility, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29508663','lexi-content-ref-21690622','lexi-content-ref-30858203','lexi-content-ref-Lowy.2','lexi-content-ref-25017183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29508663','lexi-content-ref-21690622','lexi-content-ref-30858203','lexi-content-ref-Lowy.2','lexi-content-ref-25017183'])">Ref</a></span>). Treat uncomplicated <i>S. aureus</i> bacteremia for ≥14 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric or pathogen-directed therapy for methicillin-resistant Staphylococcus epidermidis (alternative agent) (off-label use)</i>
<i>:</i>
<b>IV:</b> 6 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>); some experts recommend 8 to 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tufariello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tufariello.1'])">Ref</a></span>). Treat uncomplicated bacteremia for 5 to 7 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710','lexi-content-ref-Tufariello.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710','lexi-content-ref-Tufariello.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric or pathogen-directed therapy for vancomycin-resistant enterococci (alternative agent) (off-label use):</i>
<b>IV:</b> 8 to 12 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28011602','lexi-content-ref-23774437','lexi-content-ref-28329222','lexi-content-ref-28329222','lexi-content-ref-Murray.1','lexi-content-ref-30913322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28011602','lexi-content-ref-23774437','lexi-content-ref-28329222','lexi-content-ref-28329222','lexi-content-ref-Murray.1','lexi-content-ref-30913322'])">Ref</a></span>). May be used as part of an appropriate combination regimen, especially in critically ill patients or those with a high daptomycin minimum inhibitory concentration (MIC) (eg, 3 to 4 mcg/mL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31284042','lexi-content-ref-29374204','lexi-content-ref-Murray.1','lexi-content-ref-25017183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31284042','lexi-content-ref-29374204','lexi-content-ref-Murray.1','lexi-content-ref-25017183'])">Ref</a></span>). Treat uncomplicated bacteremia for 7 to 14 days from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19489710'])">Ref</a></span>). Some experts recommend a duration of 5 to 7 days for uncomplicated infection with rapid blood culture clearance (within 24 hours) and in the absence of metastatic infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murray.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murray.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Antibiotic lock technique (catheter-salvage strategy) (off-label use):</i>
<b>Note:</b> For infections caused by susceptible organisms when the catheter cannot be removed; use in addition to systemic antibiotics. Catheter salvage is <b>not</b> recommended for<i> S. aureus </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193593','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193593','lexi-content-ref-19489710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intracatheter:</b> Prepare lock solution to final concentration of daptomycin 1 to 5 mg/mL; may be combined with heparin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193593','lexi-content-ref-23712701','lexi-content-ref-22340450','lexi-content-ref-23403427','lexi-content-ref-25548523','lexi-content-ref-24831000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193593','lexi-content-ref-23712701','lexi-content-ref-22340450','lexi-content-ref-23403427','lexi-content-ref-25548523','lexi-content-ref-24831000'])">Ref</a></span>). Instill into each lumen of the catheter access port using a volume sufficient to fill the catheter (2 to 5 mL) with a dwell time of up to 72 hours, depending on frequency of catheter use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Girand.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Girand.1'])">Ref</a></span>). Withdraw lock solution prior to catheter use; replace with fresh daptomycin lock solution after catheter use. Antibiotic lock therapy is given for the same duration as systemic antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19193593','lexi-content-ref-19489710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19193593','lexi-content-ref-19489710'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0161ba30-daf5-44e8-a055-5635faa343ea">Cerebrospinal fluid shunt infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebrospinal fluid shunt infection (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for resistant pathogens (eg, staphylococci [including methicillin-resistant], Cutibacterium<i> acnes</i>, enterococci) or patients intolerant of other antibiotics</i>: <b>IV:</b> 6 to 10 mg/kg once daily for 10 to 14 days; for staphylococci, usually used in combination with rifampin (eg, in the setting of retained hardware) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Antony.1','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Antony.1','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intraventricular</b> (adjunct to systemic therapy; use a preservative-free preparation): 2 to 5 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24994724','lexi-content-ref-28203777','lexi-content-ref-23232018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24994724','lexi-content-ref-28203777','lexi-content-ref-23232018'])">Ref</a></span>). Additional intraventricular doses have been studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18156605','lexi-content-ref-22649456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18156605','lexi-content-ref-22649456'])">Ref</a></span>). When intraventricular daptomycin is administered via a ventricular drain, clamp drain for 15 to 60 minutes after administration (allows solution to equilibrate in cerebrospinal fluid [CSF]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>). <b>Note:</b> Intraventricular administration is generally reserved for use in patients who fail parenteral therapy despite removal of CSF shunt or when CSF shunt cannot be removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d3e4522-e8bc-4496-b3e0-f1fcdd0f13d7">Diabetic foot infection, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic foot infection, moderate to severe (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric or pathogen-directed therapy for methicillin-resistant S. aureus: </i>
<b>IV:</b> 4 to 6 mg/kg once daily. For empiric therapy, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15659542','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15659542','lexi-content-ref-Weintrob.1'])">Ref</a></span>). If concomitant osteomyelitis is present, higher doses may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26563898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26563898'])">Ref</a></span>). Duration (which may include oral step-down therapy) is usually 2 to 4 weeks in the absence of osteomyelitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22619242','lexi-content-ref-Weintrob.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ab8aa64-fefc-4e7a-9726-c9972718e6c8">Endocarditis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment:</b>
<b>Note</b>: Daptomycin should not be used in patients with concomitant pneumonia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15898002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15898002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for methicillin-resistant</i>
<i>staphylococci </i>(<i>native or prosthetic valve) (alternative</i>
<i>agent)</i>: <b>Note: </b>Reserve use for patients who cannot receive vancomycin due to intolerance or elevated MIC (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320109','lexi-content-ref-Karchmer.1','lexi-content-ref-Chu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320109','lexi-content-ref-Karchmer.1','lexi-content-ref-Chu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 8 to 10 mg/kg once daily for ≥6 weeks. For patients with prosthetic valve endocarditis, use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-Chu.1','lexi-content-ref-26320109','lexi-content-ref-21217178','lexi-content-ref-Karchmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-Chu.1','lexi-content-ref-26320109','lexi-content-ref-21217178','lexi-content-ref-Karchmer.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for penicillin-, ampicillin-, and vancomycin-resistant enterococci (native or prosthetic valve) (off-label use): </i>
<b>IV:</b> 10 to 12 mg/kg once daily as part of an appropriate combination regimen for &gt;6 weeks; may be used as monotherapy for native valve endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373316','lexi-content-ref-Chu.1','lexi-content-ref-Karchmer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373316','lexi-content-ref-Chu.1','lexi-content-ref-Karchmer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a47b3dd-219d-422b-bc94-4af729bacffc">Intracranial abscess or spinal epidural abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess, intracranial epidural abscess) or spinal epidural abscess (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for staphylococci (including methicillin-resistant):</i>
<b>IV:</b> 6 to 10 mg/kg once daily; some experts usually give in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hasbun.1','lexi-content-ref-Sexton.1','lexi-content-ref-Sexton.2','lexi-content-ref-Southwick.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hasbun.1','lexi-content-ref-Sexton.1','lexi-content-ref-Sexton.2','lexi-content-ref-Southwick.1'])">Ref</a></span>). Duration usually ranges from 4 to 8 weeks for brain abscess and spinal epidural abscess and 6 to 8 weeks for intracranial epidural abscess (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29909695','lexi-content-ref-Sexton.1','lexi-content-ref-Sexton.2','lexi-content-ref-Southwick.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29909695','lexi-content-ref-Sexton.1','lexi-content-ref-Sexton.2','lexi-content-ref-Southwick.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90b4bed4-9c84-419c-9067-b0892c7eeb49">Meningitis, bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningitis, bacterial (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for staphylococci (including methicillin-resistant):</i>
<b>IV:</b> 6 to 10 mg/kg once daily for 10 to 14 days; usually used in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777','lexi-content-ref-18636964','lexi-content-ref-Tunkel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777','lexi-content-ref-18636964','lexi-content-ref-Tunkel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c92ca38-0c20-4ec4-b5f0-113c6ccf7cd2">Osteomyelitis and/or discitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis and/or discitis (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for staphylococci (including methicillin-resistant): </i>
<b>IV:</b> 6 to 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-26563898','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-26563898','lexi-content-ref-Osmon.1'])">Ref</a></span>). Some experts combine with rifampin in the presence of retained hardware (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-21217178'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for enterococci (penicillin-susceptible or penicillin-resistant):</i>
<b>IV:</b> 6 to 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy</i>: Duration is generally ≥6 weeks. Shorter courses are appropriate if the affected bone is completely resected (eg, by amputation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26229122','lexi-content-ref-Osmon.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26229122','lexi-content-ref-Osmon.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for staphylococci (including methicillin-resistant):</i>
<b>IV:</b> 6 to 10 mg/kg once daily. Duration ranges from 2 to 6 weeks depending on prosthesis management, use of rifampin, and other patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>). <b>Note:</b> In select cases (eg, debridement and retention of prosthesis or one-stage arthroplasty), combine with oral rifampin and give oral suppressive antibiotic therapy following completion of IV treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for enterococci (penicillin-susceptible or penicillin-resistant):</i>
<b>IV:</b> 6 to 10 mg/kg once daily for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>). <b>Note:</b> In select cases (eg, debridement and retention of prosthesis or one-stage arthroplasty), give oral suppressive antibiotic therapy following completion of IV treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.1','lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9357c8a8-bc61-4588-803a-17d7cba42c78">Septic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Septic arthritis (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pathogen-directed therapy for staphylococci (including methicillin-resistant)</i>: <b>IV:</b> 6 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>). If concomitant bacteremia is present, higher doses may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178','lexi-content-ref-Lowy.1','lexi-content-ref-29235661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178','lexi-content-ref-Lowy.1','lexi-content-ref-29235661'])">Ref</a></span>). Total treatment duration is 3 to 4 weeks (in the absence of osteomyelitis), including oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1','lexi-content-ref-21217178','lexi-content-ref-28366221']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1','lexi-content-ref-21217178','lexi-content-ref-28366221'])">Ref</a></span>); some experts recommend 4 weeks of parenteral therapy for patients with concomitant bacteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goldenberg.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goldenberg.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24f33387-1a13-489f-8e63-b1a313bd7f9a">Skin and skin structure infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection (eg, erysipelas, cellulitis, necrotizing infections) (alternative agent):</b>
<b>IV:</b> 4 to 6 mg/kg once daily. Total duration of therapy is usually 5 to 14 days (including oral step-down therapy); for necrotizing infection, continue until further debridement is not necessary, patient has improved clinically, and patient is afebrile for ≥48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Stevens.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Stevens.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991433"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;130 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24030545','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24030545','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Administer usual recommended dose every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24030545','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24030545','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note</b>: High doses (&gt;8 mg/kg) have not been well studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30295740','lexi-content-ref-29559785','lexi-content-ref-33016513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30295740','lexi-content-ref-29559785','lexi-content-ref-33016513'])">Ref</a></span>); monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Patients who are young (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 10 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24046298','lexi-content-ref-26598098','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24046298','lexi-content-ref-26598098','lexi-content-ref-Expert.DOR'])">Ref</a></span>); may increase to 12 mg/kg once daily for severe infections (eg, vancomycin-resistant Enterococcus bloodstream infection or endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intermittent hemodialysis, thrice weekly: </b>Dialyzable: 51.7% ± 9.2% removed by a standard hemodialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20007981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20007981'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Every-48-hour dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>):</i>
<b> IV: </b>Follow dosing recommendations for patients with CrCl &lt;30 mL/minute (administer after hemodialysis on dialysis days).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three times weekly (post dialysis) dosing:</i>
<b> IV: </b>Administer usual recommended dose (ie, 4 or 6 mg/kg) on 48-hour interdialytic days; increase dose by 50% after dialysis on the 72-hour interdialytic day (eg, if the dose is 6 mg/kg for a patient on a Monday, Wednesday, Friday dialysis schedule, administer 6 mg/kg after dialysis on Monday and Wednesday and on Friday administer 9 mg/kg after dialysis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23208714','lexi-content-ref-21282429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23208714','lexi-content-ref-21282429'])">Ref</a></span>). Doses ≥6 mg/kg (9 mg/kg on the 72-hour interdialytic day) have not been evaluated.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Although IV administration as a 30-minute infusion or 2-minute IV push post dialysis is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24259698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24259698'])">Ref</a></span>), intradialytic administration (infused during the last hour of a 3.5-hour dialysis session) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23208714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23208714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:<b> IV:</b></b> Follow dosing recommendations for patients with CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21176752','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21176752','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Daptomycin is cleared by CRRT, and its clearance is dependent on the effluent flow rate, filter type, and method of renal replacement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32010602','lexi-content-ref-17124423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32010602','lexi-content-ref-17124423'])">Ref</a></span>). Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), along with close monitoring for adverse effects (eg, increased CPK).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 6 mg/kg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24051895','lexi-content-ref-32083673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24051895','lexi-content-ref-32083673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection), along with close monitoring for adverse effects (eg, increased CPK).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Daily PIRRT (high-flux dialyzer; blood and dialysate flow rates of 160 mL/minute; duration 8 hours): 6 mg/kg every 24 hours to be given after PIRRT ends (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21221000','lexi-content-ref-20031929','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21221000','lexi-content-ref-20031929','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988719"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doo drugH1Div" id="F53164753"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in obese patients are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Use <b>adjusted body weight</b> for weight-based dose calculations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:6em;">The use of actual body weight for weight-based dosing in patients with obesity is recommended by the manufacturer; however, some clinical data suggest significant increases in AUC and C<sub>max</sub> and a higher incidence of adverse reactions (eg, elevated CPK, myalgias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20462352','lexi-content-ref-23712701','lexi-content-ref-15601805','lexi-content-ref-17548489','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20462352','lexi-content-ref-23712701','lexi-content-ref-15601805','lexi-content-ref-17548489','lexi-content-ref-Manu.1'])">Ref</a></span>). Therefore, actual body weight should not be used in this population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17548489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17548489'])">Ref</a></span>). Some recommend fixed (nonweight-based) dosing based on pharmacokinetic modeling and Monte Carlo simulations to achieve comparable probabilities of achieving therapeutic exposures/concentrations; however, this strategy has not been validated prospectively to determine clinical outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29906315','lexi-content-ref-24046298','lexi-content-ref-31625394']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29906315','lexi-content-ref-24046298','lexi-content-ref-31625394'])">Ref</a></span>). One retrospective study utilizing a historical cohort suggests no difference in clinical failure rate in patients with BMI ≥30 kg/m<sup>2</sup> when using adjusted body weight vs actual body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30728962']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30728962'])">Ref</a></span>). Although there are methodological issues with this data, use of <b>adjusted body weight</b> may be the safer weight metric until more data become available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Higher weight-based dosing (8 to 12 mg/kg) has been recommended in select populations (eg, sepsis and/or bacteremia caused by methicillin-resistant <i>S. aureus</i>, methicillin-resistant <i>Staphylococcus</i>
<i>epidermidis</i>, vancomycin-resistant enterococci bacteremia) due to the pharmacokinetic variability observed and potential benefits with higher AUCs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28011602','lexi-content-ref-24046298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28011602','lexi-content-ref-24046298'])">Ref</a></span>). However, while higher weight-based dosing will result in higher overall AUCs, this may lead to more adverse reactions especially in patients with obesity (eg, elevated CPK, myalgias).</p></div>
<div class="block doe drugH1Div" id="F156922"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F50085848"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13009" href="/d/html/13009.html" rel="external">see "Daptomycin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b> The manufacturer recommends avoiding use in patients &lt;12 months due to musculoskeletal, neuromuscular, and nervous system adverse effects observed in neonatal canine models. Approved ages and uses for generic products may vary; consult labeling for specific information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Daptomycin should not be used for the treatment of pneumonia due to inactivation of antimicrobial activity by pulmonary surfactant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15898002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15898002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing, susceptible organisms (severe infection):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Very limited data available; due to insufficient pharmacokinetic data, optimal dosing not established:</p>
<p style="text-indent:-2em;margin-left:6em;">Young infants (eg, &lt;2 months of age): IV: 6 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2'])">Ref</a></span>); dosing was reported in a case-series including former premature and term neonates (n=3, PNA at treatment: 4 to 12 weeks; weight at treatment: 2 to 4.4 kg); one infant required a dose of 15 mg/kg/dose every 12 hours for endocarditis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22271402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22271402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: Reported range: 8 to 10 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-26484430']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-26484430'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤6 years: 10 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note</b>: Higher doses may be necessary depending on indication.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: 4 to 6 mg/kg/dose every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>). <b>Note</b>: Higher doses may be necessary depending on indication.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="546d73e9-5248-4e1d-a37b-3f8afb2a84b7">Bacteremia, due to susceptible <i>Staphylococcus aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacteremia, due to susceptible </b>
<i>
<b>Staphylococcus aureus</b></i>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Treatment duration variable based on source and clinical response; typically ≥14 days is recommended for <i>S. aureus</i> bacteremia; in trials, total treatment duration (IV and oral step-down therapy) was 5 to 28 days in patients &lt;12 years of age and 5 to 42 days in patients 12 to 17 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29406465','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29406465','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≤6 years: IV: 12 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children: 7 to ≤11 years: IV: 9 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents ≤17 years: IV: 7 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥18 years: IV: 6 mg/kg/dose every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5a67f40f-018e-41ff-8ba9-cd6f18b08451">Endocarditis due to <i>Staphylococcus</i>, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis due to <i>Staphylococcus</i> (methicillin-resistant <i>S. aureus</i> [MRSA] or vancomycin resistant/intolerant), treatment</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>): <b>Note:</b> Based on more recent pharmacokinetic/dynamic experience in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29406465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29406465'])">Ref</a></span>), AHA guideline dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>) may not be adequate and higher doses necessary in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: IV: 10 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: 6 mg/kg/dose every 24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd052341-6322-45ec-81bf-1c93c1673abd">Osteomyelitis, acute hematogenous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteomyelitis, acute hematogenous (AHO):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤6 years: IV: 12 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to ≤11 years: IV: 9 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: IV: 7 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on a randomized, controlled, non-inferiority trial (n=146, n=74 received daptomycin; ages: 1.2 to 17.3 years) comparing daptomycin to comparator (chosen based on local antibiogram) for AHO. Pathogens were isolated in 62.2% of patients receiving daptomycin (methicillin-susceptible <i>S. aureus</i> [MSSA]: 84.8%; MRSA: 8.7%). The primary objective of clinical improvement on or before day 5 occurred in 77.5% of patients receiving daptomycin and 82.9% of patients receiving comparator. Adverse events were reported more frequently in comparator (62.5%) compared to daptomycin (45.9%). In the United States, median IV treatment duration for daptomycin was 4 days (range: 1 to 21 days) before transitioning to oral step-down therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32639465']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32639465'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1bd12e9-3b0c-48ce-86de-fecb24ef20e2">Skin and skin structure infection, complicated due to susceptible <i>S. aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infection, complicated (cSSSI) due to susceptible </b>
<i>
<b>S. aureus</b></i>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children: 1 to &lt;2 years: IV: 10 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 2 to ≤6 years: IV: 9 mg/kg dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 7 to ≤11 years: IV: 7 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents ≤17 years: IV: 5 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥18 years: IV: 4 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment duration: Up to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); in clinical trials, the median duration of IV therapy was 3 days (range: 1 to 10 days) and the median duration of total therapy (IV plus oral step-down therapy) was 12 days (range: 1 to 35 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090517"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">There are no pediatric-specific recommendations in the manufacturer's labeling (has not been studied). The following dosage adjustments have been recommended based on physiologically based pharmacokinetic modeling; in patients with kidney impairment, consider monitoring CPK frequently (eg, more than once weekly) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36052120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36052120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;2 years: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Daptomycin IV Dosing Adjustments for Kidney Impairment in Children &lt;2 Years<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">eGFR</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Recommended dosing schedule: IV</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Ye 2022.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">≥30 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:0em;">(usual recommended dose)</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg/kg/dose every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">12 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 to &lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">10 mg/kg/dose every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">12 mg/kg/dose every 48 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;15 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">6 mg/kg/dose every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">8 mg/kg/dose every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to &lt;7 years: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Daptomycin IV Dosing Adjustments for Kidney Impairment in Children 2 to &lt;7 Years<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">eGFR</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Recommended dosing schedule: IV</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Ye 2022.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">≥30 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:0em;">(usual recommended dose)</p></td>
<td align="left">
<p style="text-indent:0em;">9 mg/kg/dose every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">12 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 to &lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">9 mg/kg/dose every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">12 mg/kg/dose every 48 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;15 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">7 mg/kg/dose every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">8 mg/kg/dose every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to &lt;12 years: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Daptomycin IV Dosing Adjustments for Kidney Impairment in Children 7 to &lt;12 Years<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">eGFR</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Recommended dosing schedule: IV</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Ye 2022.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">≥30 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:0em;">(usual recommended dose)</p></td>
<td align="left">
<p style="text-indent:0em;">7 mg/kg/dose every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">9 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">7 mg/kg/dose every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">9 mg/kg/dose every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents &lt;18 years: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Daptomycin IV Dosing Adjustments for Kidney Impairment in Children 12 to &lt;18 Years<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">eGFR</p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">Recommended dosing schedule: IV</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Ye 2022.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">≥30 mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:0em;">(usual recommended dose)</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg/kg/dose every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">7 mg/kg/dose every 24 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&lt;30 mL/minute/1.73 m<sup>2</sup></p></td>
<td align="left">
<p style="text-indent:0em;">5 mg/kg/dose every 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">7 mg/kg/dose every 48 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent, 3 times weekly: Note:</b> 51.7% ± 9.2% removed by a 4-hour hemodialysis session in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20007981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20007981'])">Ref</a></span>); 22.2% and 24.1% removed by a 3-hour hemodialysis session in two adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33603575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33603575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV: Based on limited data in adults and a 5-year-old pediatric patient, administer usual recommended dose every 48 hours; on dialysis days, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chan.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chan.1','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> In one study, adolescent patients receiving 3-times-weekly dialysis were administered usual dose on Monday and Wednesday, and given a 50% increased dose on Friday to account for longer interdialytic time (eg, if the dose is 5 mg/kg for a patient who is receiving dialysis on Monday, Wednesday, and Friday, administer 5 mg/kg after dialysis on Monday and Wednesday and on Friday administer 7.5 mg/kg after dialysis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33603575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33603575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: Based on limited data in adults and pediatric patients 12 to 15 years of age, consider administering usual recommended dose every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21176752','lexi-content-ref-33603575','lexi-content-ref-28943826','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21176752','lexi-content-ref-33603575','lexi-content-ref-28943826','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51090518"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56411278"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Clostridioides difficile infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antibiotics, including daptomycin, have been associated with <i>Clostridioides difficile</i> infection (CDI), including <i>Clostridioides difficile</i> associated diarrhea and <i>Clostridioides difficile</i> colitis; however, daptomycin is associated with a lower risk for CDI compared to other high-risk antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31964789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31964789'])">Ref</a></span>). In addition, some data has suggested efficacy of daptomycin against <i>C. difficile</i> in vitro (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3036501','lexi-content-ref-19732094','lexi-content-ref-16870765','lexi-content-ref-31964789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3036501','lexi-content-ref-19732094','lexi-content-ref-16870765','lexi-content-ref-31964789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non–dose-related; antibiotics disrupt the indigenous gut microbiota which promotes <i>C. difficile</i> spore germination, growth, and toxin production, leading to epithelial damage and colitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24503131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24503131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in general, antibiotic-associated CDI may start on the first day of antibiotic therapy or up to 3 months postantibiotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22146873','lexi-content-ref-29053792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22146873','lexi-content-ref-29053792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i> Antibiotics in general:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Antibiotic exposure (highest risk factor); antibiotics most frequently associated with <i>C. difficile </i>include clindamycin, fluoroquinolones, third-/fourth-generation cephalosporins, and carbapenems (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341','lexi-content-ref-31964789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478961','lexi-content-ref-CDC.1','lexi-content-ref-24755188','lexi-content-ref-23620467','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341','lexi-content-ref-31964789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Long durations in a hospital or other health care setting (recent or current) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-29053792','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Immunocompromised conditions or serious underlying conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>GI surgery/manipulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Antiulcer medications, such as proton pump inhibitors and H<sub>2</sub> blockers (suggested risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-29462280','lexi-content-ref-27216385','lexi-content-ref-29272341'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Chemotherapy (suggested risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Eosinophilic pneumonia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Daptomycin-induced <b>eosinophilic </b>
<b>pneumonitis </b>(or eosinophilic interstitial pneumonia) has been reported. It is characterized by new-onset dyspnea, fever, bilateral infiltrates, and/or &gt;25% eosinophils in bronchoalveolar lavage. Peripheral eosinophilia and fine crackles have also been commonly observed in case reports. Most cases reported improvement after daptomycin discontinuation; however, some patients developed chronic pneumonitis and required long-term corticosteroid treatment. However, literature does support a temporal association between daptomycin exposure and the development of eosinophilic pneumonia. Recurrence upon rechallenge has also been observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29791122','lexi-content-ref-33870898','lexi-content-ref-29369189','lexi-content-ref-27259674','lexi-content-ref-25758082','lexi-content-ref-29093391','lexi-content-ref-22612850','lexi-content-ref-30397557','lexi-content-ref-28406091','lexi-content-ref-29225987','lexi-content-ref-33889339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29791122','lexi-content-ref-33870898','lexi-content-ref-29369189','lexi-content-ref-27259674','lexi-content-ref-25758082','lexi-content-ref-29093391','lexi-content-ref-22612850','lexi-content-ref-30397557','lexi-content-ref-28406091','lexi-content-ref-29225987','lexi-content-ref-33889339'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>There have been several mechanisms suggested for daptomycin eosinophilic pneumonia with one centered on daptomycin accumulating and binding to pulmonary surfactant. This has been thought to cause direct or indirect damage to the pulmonary epithelium with resulting inflammation. Of note, one study found an association with development of eosinophilic pneumonia and cumulative dose or duration, while another study did not find this association. An allergic mechanism has also been suggested that attributes the pathophysiology to an antigen-mediated process in which alveolar macrophages and T-helper 2 (Th2) lymphocyte cells are activated, which then cause the subsequent release of interleukin-5, leading to an influx of eosinophils to the lungs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29369189','lexi-content-ref-29093391','lexi-content-ref-28003110','lexi-content-ref-33923382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29369189','lexi-content-ref-29093391','lexi-content-ref-28003110','lexi-content-ref-33923382'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; usually 10 days to 4 weeks after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22612850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22612850'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i>
<b>Note:</b> Risk factors for this condition have not been well established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33870898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33870898'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28003110','lexi-content-ref-27999664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28003110','lexi-content-ref-27999664'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28003110','lexi-content-ref-33923382','lexi-content-ref-27999664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28003110','lexi-content-ref-33923382','lexi-content-ref-27999664'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions (<b>urticaria</b>, <b>angioedema</b>, <b>anaphylaxis</b>) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27228997','lexi-content-ref-18254489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27228997','lexi-content-ref-18254489'])">Ref</a></span>). Delayed hypersensitivity reactions have also been reported, including <b>skin rash</b>, <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS), and <b>acute generalized exanthematous pustulosis</b> (AGEP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24999649','lexi-content-ref-24583445','lexi-content-ref-22346259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24999649','lexi-content-ref-24583445','lexi-content-ref-22346259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria) are IgE-mediated. Delayed hypersensitivity reactions, including AGEP, are T-cell mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration, but may occur 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-27228997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-27228997'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; rashes usually begin 6 to 10 days after initiation. Severe cutaneous adverse reactions, including DRESS and AGEP, occur days to 8 weeks after drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-24999649','lexi-content-ref-22346259','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-24999649','lexi-content-ref-22346259','lexi-content-ref-NICE.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Myopathy and rhabdomyolysis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Daptomycin may cause symptomatic or asymptomatic <b>increased</b>
<b>creatine phosphokinase in blood specimen </b>(CPK) (or creatine kinase) in pediatrics and adults. Use is also associated with significant CPK elevations (&gt;10 times the upper limit of normal [ULN]) and skeletal muscle toxicities, such as <b>myopathy </b>and<b> rhabdomyolysis </b>(including cases of acute renal failure and/or liver injury secondary to the rhabdomyolysis). Case reports of daptomycin-induced rhabdomyolysis have occurred in the setting of monotherapy and with concomitant use of another medication, particularly an HMG CoA-reductase inhibitor (ie, a statin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21958456','lexi-content-ref-21965434','lexi-content-ref-22511636','lexi-content-ref-29668884','lexi-content-ref-16914701','lexi-content-ref-30430398','lexi-content-ref-16410267','lexi-content-ref-30689699','lexi-content-ref-24801642','lexi-content-ref-30423035','lexi-content-ref-19346518','lexi-content-ref-28471867','lexi-content-ref-31673242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21958456','lexi-content-ref-21965434','lexi-content-ref-22511636','lexi-content-ref-29668884','lexi-content-ref-16914701','lexi-content-ref-30430398','lexi-content-ref-16410267','lexi-content-ref-30689699','lexi-content-ref-24801642','lexi-content-ref-30423035','lexi-content-ref-19346518','lexi-content-ref-28471867','lexi-content-ref-31673242'])">Ref</a></span>). Daptomycin-induced CPK elevation is reversible upon discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26711755','lexi-content-ref-22511636','lexi-content-ref-29559785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26711755','lexi-content-ref-22511636','lexi-content-ref-29559785'])">Ref</a></span>). Therapy discontinuation is warranted in patients with significant CPK elevations, which the prescribing information defines as an increase in CPK &gt;5 times ULN (or 1,000 units/L) in patients with signs/symptoms of myopathy <b>OR</b> an increase in CPK ≥10 times ULN (or &gt;2,000 units/L) in asymptomatic patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Exact mechanism is unknown, but it is believed that similar to daptomycin’s mechanism of action in bacterial cells that causes release of intracellular ions, it may also affect myocytes in skeletal muscles resulting in leakage of intracellular CPK (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19346518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19346518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; in a case control study, the mean onset of CPK elevation was 16.7 days (range: 1 to 58 days), the mean onset for myopathy was 25 days (range: 3 to 176 days), and the mean onset for rhabdomyolysis was 13 days (range: 1 to 24 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Risk factors: </i>
<b>Note:</b> A number of risk factors have been suggested, but overall data regarding risk factors are limited, unclear, and conflicting.</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant statin therapy (potential risk factor suggested by some observational studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29668884','lexi-content-ref-34117712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29668884','lexi-content-ref-34117712'])">Ref</a></span>); however, other observational studies have failed to find a significant association) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25022580','lexi-content-ref-30689699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25022580','lexi-content-ref-30689699'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (BMI &gt;25 kg/m<sup>2</sup>) (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20462352','lexi-content-ref-23712701','lexi-content-ref-29668884','lexi-content-ref-34117712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20462352','lexi-content-ref-23712701','lexi-content-ref-29668884','lexi-content-ref-34117712'])">Ref</a></span>) <b>Note: </b>Patients with obesity have lower daptomycin clearance potentially resulting in greater exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34117712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34117712'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Critically ill patients/hypoxic conditions, such as severe sepsis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16705566','lexi-content-ref-32581153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16705566','lexi-content-ref-32581153'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Daptomycin exposure:</p>
<p style="text-indent:-2em;margin-left:8em;">- Dosing intervals more frequent than the recommended once-daily regimen (suggested by earlier phase, dose-finding human and animal studies where daptomycin was administered more frequently than once daily) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12654665','lexi-content-ref-11036005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12654665','lexi-content-ref-11036005'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Trough levels ≥24.3 mg/L has been suggested as a potential risk factor increasing the risk of CPK elevations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20462352','lexi-content-ref-26711755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20462352','lexi-content-ref-26711755'])">Ref</a></span>); however, other data have not found a significant association (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31696963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31696963'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Severe renal impairment (potential risk factor; conflicting evidence exists) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29559785','lexi-content-ref-33016513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29559785','lexi-content-ref-33016513'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Peripheral neuropathy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cases of <b>peripheral neuropathy</b> have been reported. There is also a single published case report of external popliteal sciatic nerve paralysis with daptomycin therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29383748']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29383748'])">Ref</a></span>). In addition, in a clinical trial evaluating daptomycin for bacteremia and endocarditis due to <i>Staphylococcus aureus</i>, an increased incidence of adverse events related to the peripheral nervous system (eg, <b>paresthesia</b>, dysesthesias, and peripheral neuropathies) were observed in patients receiving daptomycin compared to those receiving standard therapy; however, the authors described these events as mild to moderate, mostly short-lived, and resolving with continued treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16914701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16914701'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F156892"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and pediatric patients unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Vomiting (children and adolescents: 3% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (adults: 7%), edema (adults: 7%), hypertension (adults: 6%), hypotension (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (adults: 5%), pruritus (3% to 6%), skin rash (adults: 4%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Daptomycin: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Daptomycin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Vancomycin or an Anti-Staphylococcal Semi-Synthetic Penicillin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Daptomycin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Vancomycin or an Anti-Staphylococcal Semi-Synthetic Penicillin)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complicated skin and skin structure infections</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">534</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">558</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (adults: 6%; children and adolescents: 2%), diarrhea (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (adults: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacteremia (adults: 5%), gram-negative organism infection (adults: 8%), sepsis (adults: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (adults: 2%), headache (3% to 5%), insomnia (adults: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (3% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Increased Creatine Phosphokinase in Blood Specimen table link" class="lexi-table-link" data-table-id="lexi-content-increased-creatine-phosphokinase-in-blood-specimen" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-creatine-phosphokinase-in-blood-specimen')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Creatine Phosphokinase in Blood Specimen</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Creatine Phosphokinase in Blood Specimen" frame="border" id="lexi-content-increased-creatine-phosphokinase-in-blood-specimen" rules="all">
<caption style="text-align:center;">
<b>Daptomycin: Adverse Reaction: Increased Creatine Phosphokinase in Blood Specimen</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Daptomycin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Vancomycin, Clindamycin, Cefazolin, or an Anti-Staphylococcal Semi-Synthetic Penicillin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Daptomycin)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Age specific dosing (7 mg/kg to 12 mg/kg)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<i>S. aureus</i> bacteremia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">55</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">26</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Children and Adolescents</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Age specific dosing (5 mg/kg to 10 mg/kg)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complicated skin and skin structure infections</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">256</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">133</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<i>S. aureus</i> bacteremia/endocarditis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">120</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">116</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Complicated skin and skin structure infections</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">534</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">558</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (adults: 2%), pharyngolaryngeal pain (adults: 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (children and adolescents: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, supraventricular cardiac arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Electrolyte disturbance, hypomagnesemia, increased lactate dehydrogenase, increased serum bicarbonate</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension, dysgeusia, stomatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, increased INR, leukocytosis, thrombocythemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, mental status changes, myasthenia, paresthesia, rigors, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, asthenia, muscle cramps, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye irritation</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, atrial flutter</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Vesicular eruption</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum phosphate</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite, epigastric distress, gingival pain, oral candidiasis, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Fungal urinary tract infection, proteinuria, vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis, fungal septicemia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hallucination, hypoesthesia (oral)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Gordon Spratt 2014), erythema of skin (Caulder 2014), Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria (Metz 2008), vesiculobullous dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (Budovich 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: <i>Clostridioides difficile</i> associated diarrhea (Webb 2020), dysphagia, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, myoglobin increased, neutropenia (Knoll 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Abraham 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Gisler 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy (Villaverde Piñeiro 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy (Hagiya 2015), rhabdomyolysis (King 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Bosak 2016), acute kidney injury (Abraham 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchiolitis obliterans organizing pneumonia, cough, eosinophilic pneumonitis (Higashi 2018)</p></div>
<div class="block coi drugH1Div" id="F156907"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to daptomycin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F156890"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interstitial nephritis, acute: Interstitial nephritis has been reported. Evaluate patients with new or worsening renal impairment; discontinue and institute appropriate treatment if suspected.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Persisting or relapsing <i>S. aureus</i> bacteremia or endocarditis: Repeat blood cultures in patients with persisting or relapsing <i>S. aureus</i> bacteremia/endocarditis or poor clinical response. If culture is positive for <i>S. aureus</i>, perform minimum inhibitory concentration (MIC) susceptibility testing of the isolate and diagnostic evaluation of the patient to rule out sequestered foci of infection. Appropriate surgical intervention (eg, debridement, removal of prosthetic devices, valve replacement surgery) and/or consideration of a change in antibacterial therapy may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe renal impairment (CrCl &lt;30 mL/minute). Limited data (eg, subgroup analysis) from cSSSI and endocarditis trials suggest possibly reduced clinical efficacy (relative to comparators) in patients with baseline moderate to severe renal impairment (&lt;50 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid use in pediatric patients &lt;12 months due to risk of potential muscular, neuromuscular, and/or nervous systems effects observed in neonatal canines.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex: Some products may contain latex.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878407"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Avoiding use in neonatal and pediatric patients &lt;12 months is recommended in product labeling; neonatal animal models (canine) have shown reversible musculoskeletal, neuromuscular, and nervous system adverse effects including twitching, muscle rigidity of the limbs, and impaired use of the limbs; adverse effects were observed at lower serum concentrations than older canine models (approximately threefold less than juvenile models and ninefold less than adult models) and resolved within 28 days of discontinuation. The neuromuscular/skeletal adverse events occurred with canine doses and drug exposure levels that were higher than the standard adult human dose (6 mg/kg) and corresponding daptomycin exposure levels. Nervous system adverse effects are most associated with high peak serum concentrations; to mitigate this risk and lower patient's exposure, longer infusion times are used in pediatric patients (ie, age ≤6 years: Infuse over 60 minutes; &gt;6 years of age: Infuse over 30 minutes vs adolescents ≥18 years: Bolus over 2 minutes) (Arrieta 2018). Evaluate risk vs benefit when considering use in neonates and infants.</p></div>
<div class="block prod-avail drugH1Div" id="F56556162"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Dapzura RT: FDA approved January 2022; anticipated availability currently unknown. Information pertaining to this product within the monograph is pending revision. Dapzura RT contains sorbitol. Consult the prescribing information for additional information.</p></div>
<div class="block foc drugH1Div" id="F156900"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1000 mg (100 mL); 350 mg (50 mL); 500 mg (50 mL); 700 mg (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 350 mg (1 ea); 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cubicin: 500 mg (1 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cubicin RF: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 350 mg (1 ea); 500 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F156888"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323093"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DAPTOmycin-Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">350 mg/50 mL 0.9% (per mL): $0.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL 0.9% (per mL): $0.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">700 mg/100 mL 0.9% (per mL): $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/100 mL 0.9% (per mL): $0.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cubicin RF Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $534.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (DAPTOmycin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">350 mg (per each): $16.36 - $332.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $22.31 - $534.58</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866515"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cubicin: 500 mg ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cubicin RF: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F156904"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as an IV infusion over 30 minutes. May also administer IV push over 2 minutes. Do not use in conjunction with ReadyMED elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) leaching from the pump system into the daptomycin solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Intraventricular (off-label route): Use preservative-free preparations only. When administered through a ventricular drain, clamp drain for 15 to 60 minutes before opening the drain to allow daptomycin solution to equilibrate in the cerebrospinal fluid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612483"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Intermittent IV infusion:</p>
<p style="text-indent:-2em;margin-left:2em;">Neonates: Infusion over 60 minutes has been reported in trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22627869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22627869'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Infants &lt;3 months: Infusion over 30 or 60 minutes has been reported in trials with every 12-hour dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22271402','lexi-content-ref-22627869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22271402','lexi-content-ref-22627869'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Infants ≥3 months: Infusion over 30 minutes has been reported in trials; a longer infusion time of 60 minutes may be considered to minimize exposure to high peak serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29406465','lexi-content-ref-25361023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29406465','lexi-content-ref-25361023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Children 1 to 6 years: Infuse over 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Children ≥7 years and Adolescents: Infuse over 30 minutes.</p>
<p style="text-indent:0em;margin-top:2em;">Do not use in conjunction with ReadyMED elastomeric infusion pumps (Cardinal Health, Inc) due to an impurity (2-mercaptobenzothiazole) which leaches from the pump system into the daptomycin solution.</p></div>
<div class="block use drugH1Div" id="F156903"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection:</b> Treatment of bloodstream infection caused by <i>Staphylococcus aureus</i> (methicillin-susceptible and methicillin-resistant isolates) in adults, including those with right-sided infective endocarditis; treatment of bloodstream infection due to <i>S. aureus</i> in pediatric patients 1 to 17 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and skin structure infections, complicated:</b> Treatment of complicated skin and skin structure infections caused by <i>S. aureus</i> (including methicillin-resistant isolates), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, <i>Streptococcus dysgalactiae</i> subspecies <i>equisimilis</i>, and <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates only) in adult and pediatric patients 1 to 17 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for the treatment of pneumonia.</p></div>
<div class="block off-label drugH1Div" id="F25475182"><span class="drugH1">Use: Off-Label: Adult</span><p>Cerebrospinal fluid shunt infection; Diabetic foot infections; Endocarditis, treatment; Intracranial abscess (brain abscess, intracranial epidural abscess) or spinal epidural abscess; Meningitis, bacterial; Osteomyelitis and/or discitis; Prosthetic joint infection; Septic arthritis</p></div>
<div class="block mst drugH1Div" id="F3265806"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cubicin may be confused with Cleocin, Cubicin RF</p>
<p style="text-indent:-2em;margin-left:4em;">Cubicin RF may be confused with Cubicin</p>
<p style="text-indent:-2em;margin-left:4em;">DAPTOmycin may be confused with DACTINomycin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Storage and preparations errors have occurred when Cubicin has been confused with Cubicin RF (ISMP 2016)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Daptomycin, when used in neonates and infants &lt;1 year of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of neuromuscular and skeletal adverse events (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299126"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F156894"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): May enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased. Management: Consider temporarily stopping statin (HMG-CoA reductase inhibitor) therapy prior to daptomycin. If daptomycin is used with a statin, creatine phosphokinase (CPK) monitoring could be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May decrease the serum concentration of DAPTOmycin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: May enhance the adverse/toxic effect of DAPTOmycin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F156909"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies. Successful use of daptomycin during the second and third trimesters of pregnancy has been described; however, only limited information is available from case reports.</p></div>
<div class="block brc drugH1Div" id="F6063936"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Low concentrations of daptomycin have been detected in breast milk; however, daptomycin is poorly absorbed orally. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Monitor infants for GI disturbances (WHO 2002).</p></div>
<div class="block mop drugH1Div" id="F156898"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor signs and symptoms of infection. CPK should be monitored at least weekly during therapy; more frequent monitoring if current or prior statin therapy, unexplained CPK increases, and/or renal impairment. Monitor for muscle pain or weakness, especially if noted in distal extremities. Monitor for new onset or worsening peripheral neuropathy. Monitor for signs/symptoms of eosinophilic pneumonia (eg, new-onset or worsening fever, dyspnea, difficulty breathing, new infiltrates on chest imaging studies, and/or &gt;25% eosinophils present in bronchoalveolar lavage). Monitor for signs/symptoms of hypersensitivity reactions, including DRESS (eg, fever, peripheral eosinophilia, rash, systemic organ impairment [eg, hepatic, pulmonary, renal]).</p></div>
<div class="block rer drugH1Div" id="F156901"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Trough concentrations at steady-state:</p>
<p style="text-indent:-2em;margin-left:4em;">4 mg/kg once daily: 5.9 ± 1.6 mcg/mL</p>
<p style="text-indent:-2em;margin-left:4em;">6 mg/kg once daily: 6.7 ± 1.6 mcg/mL</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Routine trough monitoring is not recommended. Trough concentrations are not predictive of efficacy. Drug exhibits concentration-dependent bactericidal activity, so C<sub>max</sub>:MIC ratios may be a more useful parameter for efficacy.</p></div>
<div class="block pha drugH1Div" id="F156889"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Daptomycin binds to components of the cell membrane of susceptible organisms and causes rapid depolarization, inhibiting intracellular synthesis of DNA, RNA, and protein. Daptomycin is bactericidal in a concentration-dependent manner.</p></div>
<div class="block phk drugH1Div" id="F156906"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and Infants &lt;3 months of age: Median: 0.21 L/kg (range: 0.11 to 0.34 L/kg) (Cohen-Wolkowiez 2012).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to 6 years of age: 0.14 L/kg (Abdel-Rahman 2008; Abdel-Rahman 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 7 to 17 years of age: 0.11 ± 0.02 L/kg (Abdel-Rahman 2008).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 0.1 L/kg; Critically-ill patients: V<sub>ss</sub>: 0.23 ± 0.14 L/kg (Vilay 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Bone (cancellous): <i>f</i>C<sub>max</sub> (plasma)/<i>f</i>C<sub>max</sub> (tissue) ratio, steady state: 75%; <i>f</i>AUC<sub>tissue</sub>/<i>f</i>AUC<sub>plasma</sub> ratio, steady state: 117% (Traunmüller 2010); bone/plasma ratio, single dose, ~7 hours postdose: ~8% to 10% (Montange 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">CSF:plasma ratio: AUC<sub>24</sub> 0.45%; C<sub>max</sub> 0.24% (Piva 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Synovial fluid, single dose, ~7 hours postdose:plasma ratio ~54% (Montange 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 90% to 93%; 84% to 88% in patients with CrCl &lt;30 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minor amounts of oxidative metabolites have been detected.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and infants &lt;3 months of age: Median: 6.2 hours (range: 3.7 to 9 hours) (Cohen-Wolkowiez 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years of age: Mean range: 5.3 to 5.7 hours (Abdel-Rahman 2008; Abdel-Rahman 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to 11 years of age: 5.6 ± 2.2 hours (Abdel-Rahman 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 12 to 17 years of age: 6.7 ± 2.2 hours (Abdel-Rahman 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 8 to 9 hours (up to 28 hours in renal impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (78%; primarily as unchanged drug); feces (5.7%).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and infants &lt;3 months of age: Median: 21 mL/hour/kg (range: 16 to 34 mL/hour/kg) (Cohen-Wolkowiez 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 6 years of age: 19 to 20 mL/hour/kg (Abdel-Rahman 2008; Abdel-Rahman 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 7 to 11 years of age: 17 mL/hour/kg (Abdel-Rahman 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 12 to 17 years of age: 11 mL/hour/kg (Abdel-Rahman 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 8.3 to 9 mL/hour/kg.</p></div>
<div class="block phksp drugH1Div" id="F51220915"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean total plasma clearance was 9%, 22%, and 46% lower in patients with mild (CrCl 50 to 80 mL/minute), moderate (CrCl 30 to &lt;50 mL/minute), and severe (CrCl &lt;30 mL/minute) renal impairment, respectively, compared with those with healthy renal function. Mean AUC, half-life, and V<sub>d</sub> at steady state increased with decreasing renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In neonates and pediatric patients &lt;12 years of age, clearance and volume of distribution are higher than older populations; these patients require higher mg/kg doses or more frequent dosing to achieve adequate serum concentrations and systemic exposure (Principi 2015)</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Mean total clearance is reduced ~35% and AUC is increased ~58% in elderly patients compared with younger healthy subjects.</p>
<p style="text-indent:-2em;margin-left:2em;">Obesity: Plasma clearance was 15% and 23% lower and AUC increased by 30% and 31% in moderately obese patients and extremely obese patients, respectively, compared with nonobese controls.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Gram-positive infection: Concentration dependent, associated with AUC<sub>24</sub>/minimum inhibitory concentration (MIC), goal: &gt;400 (bacteriostatic), ≥666 (reduced mortality) (Falcone 2013a), &gt;800 (bactericidal) (Di Paolo 2013), and <i>f</i>C<sub>max </sub>(peak)/MIC, goal: 2.5 to 7 (bacteriostatic); 7 to 25 (2-log kill) (Safdar 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Pathogen specific:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>E. faecalis: f</i>AUC<sub>24</sub>/MIC ≥7.2 (bacteriostatic) (Kidd 2018).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Enterococcus faecium:</i> C<sub>max</sub>/MIC ≥0.14 to 0.25 (bacteriostatic); AUC<sub>24</sub>/MIC ≥0.94 to 1.67 (bacteriostatic) (Safdar 2004); <i>f</i>AUC<sub>24</sub>/MIC ≥0.85 (bacteriostatic); ≥12.9 (1-log kill) (Kidd 2018).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>S. aureus:</i> C<sub>max</sub>/MIC ≥59 to 94 (bacteriostatic); AUC<sub>24</sub>/MIC ≥388 to 537 (bacteriostatic) (Safdar 2004); <i>f</i>AUC<sub>24</sub>/MIC ≥42 to 43 (stasis) (Louie 2001; Safdar 2004).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Streptococcus pneumoniae</i>: C<sub>max</sub>/MIC ≥12 to 36 (bacteriostatic); AUC<sub>24</sub>/MIC ≥75 to 237 (bacteriostatic) (Safdar 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in patients with normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AUC<sub>24</sub>:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients with bacteremia:</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to 6 years: 12 mg/kg once daily: 620 ± 109 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 7 to 11 years: 9 mg/kg once daily: 579 ± 116 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children and Adolescents 12 to 17 years: 7 mg/kg once daily: 656 ± 334 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults (healthy):</p>
<p style="text-indent:-2em;margin-left:10em;">6 mg/kg once daily: 632 ± 78 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">8 mg/kg once daily: 858 ± 213 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">10 mg/kg once daily: 1,039 ± 178 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">12 mg/kg once daily: 1,277 ± 254 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:6em;">C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients with bacteremia:</p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to 6 years: 12 mg/kg once daily: 106 ± 12.8 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 7 to 11 years: 9 mg/kg once daily: 104 ± 14.5 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">Children and Adolescents 12 to 17 years: 7 mg/kg once daily: 104 ± 35.5 mg/L.</p>
<p style="text-indent:-2em;margin-left:8em;">Adults (healthy):</p>
<p style="text-indent:-2em;margin-left:10em;">6 mg/kg once daily: 93.9 ± 6 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">8 mg/kg once daily: 123.3 ± 16 mg/L.</p>
<p style="text-indent:0em;margin-left:8em;">10 mg/kg once daily: 141.1 ± 24 mg/L.</p>
<p style="text-indent:-2em;margin-left:10em;">12 mg/kg once daily: 183.7 ± 25 mg/L.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Bacterial killing continues after daptomycin concentration falls below the MIC of targeted pathogen and varies based on the organism:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>E. faecalis</i>: 0.6 to 6.7 hours, dose dependent (Hanberger 1991).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. aureus</i>: 1 to 6.3 hours (Hanberger 1991; Pankuch 2003; Safdar 2004).</p>
<p style="text-indent:-2em;margin-left:8em;">Methicillin-susceptible <i>S. aureus</i>: Mean: 2.4 hours (Pankuch 2003).</p>
<p style="text-indent:-2em;margin-left:8em;">Methicillin-resistant <i>S. aureus</i>: Mean: 4.1 hours (Pankuch 2003).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>S. pneumoniae:</i> 1 to 2.5 hours (mean: 1.7 hours) (Pankuch 2003); postantibiotic effect of up to 10.8 hours has been observed at a dose of 10 mg/kg (Safdar 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with toxicity:</i> C<sub>min</sub> (trough) (steady state) ≥24.3 mg/L associated with increased risk of CPK elevation (Abdul-Aziz 2020; Bhavnani 2010).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539841"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Cubicin rf</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Cubicin rt</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin accordpharma | Daptomycin betapharm | Daptomycin norameda</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin accord | Daptomycin dr.reddys | Daptomycin juno | Pfizer daptomycin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomicina | Daptomicina accord farma | Dopcym | Exfuno | Trisk</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin accord | Daptomycin labatec</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomicina | Daptomred | Databin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Daptomycin accordpharma</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin accord | Daptomycin beta | Daptomycin cipla | Daptomycin Hikma | Daptomycin noridem | Daptomycin panpharma | Daptomycin ratiopharm</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin norameda</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomicina accord | Daptomicina aristo | Daptomicina cipla | Daptomicina dr reddys | Daptomicina normon | Daptomicina sala | Daptomicina tillomed | Daptomicina xellia</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Daptomycin accordpharma | Daptomycin norameda</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycine Accord | Daptomycine hikma | Daptomycine hospira | Daptomycine medac | Daptomycine noridem | Daptomycine Reddy | Daptomycine xellia</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin/accordpharma | Daptomycin/demo | Zepraxen</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin anfarm | Daptomycin hameln | Daptomycin hospira</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin accordpharma</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptobio | Daptovan | Ivdapt</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomicina accord | Daptomicina Dr. Reddy's | Daptomicina Teva Generics | Daptomicina tillomed</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Xeracine</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung daptomycin | Daptocin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cubicin rf</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cubicine</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin Hikma | Daptomycine eureco pharma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Daptomycin accordpharma</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Cubicin rf</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomicina accord | Daptomicina normon</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Cubicin RF | Xeracine</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin psk</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Daci | Docine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin accordpharma | Daptomycin stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptocin | Daptomax | Dupcin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Daptomycin vista</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cubicin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cubicin | Cusyn | Drymred</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18316988">
<a name="18316988"></a>Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. <i>Pediatr Infect Dis J.</i> 2008;27(4):330-334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18316988/pubmed" id="18316988" target="_blank">18316988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21317681">
<a name="21317681"></a>Abdel-Rahman SM, Chandorkar G, Akins RL, et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved gram-positive infections. <i>Pediatr Infect Dis J.</i> 2011;30(8):712-714.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21317681/pubmed" id="21317681" target="_blank">21317681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med</i>. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29791122">
<a name="29791122"></a>Abelenda Alonso G, Montes Rodríguez I, Martín Torres J, Del Valle Loarte P. Daptomycin eosinophilic pneumonia: an adverse effect to be aware of. <i>Rev Esp Quimioter</i>. 2018;31(3):282-284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29791122/pubmed" id="29791122" target="_blank">29791122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18381844">
<a name="18381844"></a>Abraham G, Finkelberg D, Spooner LM. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. <i>Ann Pharmacother</i>. 2008;42(5):719-721. doi:10.1345/aph.1K579<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18381844/pubmed" id="18381844" target="_blank">18381844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33870898">
<a name="33870898"></a>Ahouansou N, Georges M, Beltramo G, Aswad N, Hassani Y, Bonniaud P. Daptomycin-induced eosinophilic pneumonia: Are there any risk factors? <i>Infect Dis Now</i>. 2021;51(7):618-621. doi:10.1016/j.idnow.2021.01.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/33870898/pubmed" id="33870898" target="_blank">33870898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31696963">
<a name="31696963"></a>Ando M, Nishioka H, Nakasako S, et al. Observational retrospective single-centre study in Japan to assess the clinical significance of serum daptomycin levels in creatinine phosphokinase elevation. <i>J Clin Pharm Ther</i>. 2020;45(2):290-297. doi:10.1111/jcpt.13061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/31696963/pubmed" id="31696963" target="_blank">31696963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22271402">
<a name="22271402"></a>Antachopoulos C, Iosifidis E, Sarafidis K, et al. Serum levels of daptomycin in pediatric patients. <i>Infection</i>. 2012;40(4):367-371.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22271402/pubmed" id="22271402" target="_blank">22271402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Antony.1">
<a name="Antony.1"></a>Antony SJ, Hoffman-Roberts HL, Foote BS. Use of daptomycin as salvage therapy in the treatment of central nervous system infections including meningitis and shunt infections. <i>Infect Dis Clin Pract</i>. 2012;20(2):161-163.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29406465">
<a name="29406465"></a>Arrieta AC, Bradley JS, Popejoy MW, et al. Randomized multicenter study comparing safety and efficacy of daptomycin versus standard of care in pediatric patients with staphylococcal bacteremia. <i>Pediatr Infect Dis J</i>. 2018;37(9):893-900. doi:10.1097/INF.0000000000001926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29406465/pubmed" id="29406465" target="_blank">29406465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31284042">
<a name="31284042"></a>Avery LM, Kuti JL, Weisser M, et al. Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>Int J Antimicrob Agents</i>. 2019;54(3):346-350. doi:10.1016/j.ijantimicag.2019.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/31284042/pubmed" id="31284042" target="_blank">31284042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.1">
<a name="Berbari.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Flynn PM, Fekete T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373316">
<a name="26373316"></a>Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. <i>Circulation</i>. 2015;132(15):1435-1486. doi:10.1161/CIR.0000000000000296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26373316/pubmed" id="26373316" target="_blank">26373316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi:10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29369189">
<a name="29369189"></a>Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: a review of 196 case reports. <i>Medicine (Baltimore)</i>. 2018;97(4):e9688. doi:10.1097/MD.0000000000009688<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29369189/pubmed" id="29369189" target="_blank">29369189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21694874">
<a name="21694874"></a>Beneri CA, Nicolau DP, Seiden HS, et al. Successful Treatment of a Neonate With Persistent Vancomycin-Resistant Enterococcal Bacteremia With a Daptomycin-Containing Regimen. <i>Infect Drug Resist</i>. 2008;1:9-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21694874/pubmed" id="21694874" target="_blank">21694874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21176752">
<a name="21176752"></a>Benziger DP, Pertel PE, Donovan J, et al. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis. <i>Clin Nephrol</i>. 2011;75(1):63-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21176752/pubmed" id="21176752" target="_blank">21176752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26711755">
<a name="26711755"></a>Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL. Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. <i>Antimicrob Agents Chemother</i>. 2015;60(3):1600-1607. doi:10.1128/AAC.02967-15<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26711755/pubmed" id="26711755" target="_blank">26711755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20462352">
<a name="20462352"></a>Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. <i>Clin Infect Dis</i>. 2010;50(12):1568-1574. doi:10.1086/652767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20462352/pubmed" id="20462352" target="_blank">20462352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25022580">
<a name="25022580"></a>Bland CM, Bookstaver PB, Lu ZK, Dunn BL, Rumley KF; Southeastern Research Group Endeavor (SERGE-45). Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. <i>Antimicrob Agents Chemother</i>. 2014;58(10):5726-5731. doi:10.1128/AAC.02910-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25022580/pubmed" id="25022580" target="_blank">25022580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21958456">
<a name="21958456"></a>Bland CM, Bookstaver PB, Thomas S. Successful re-challenge of daptomycin therapy after initial rhabdomyolysis with co-administration of simvastatin. <i>Int J Antimicrob Agents</i>. 2011;38(6):549-550. doi:10.1016/j.ijantimicag.2011.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21958456/pubmed" id="21958456" target="_blank">21958456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29909695">
<a name="29909695"></a>Bodilsen J, Brouwer MC, Nielsen H, Van De Beek D. Anti-infective treatment of brain abscess. <i>Expert Rev Anti Infect Ther.</i> 2018;16(7):565-578. doi:10.1080/14787210.2018.1489722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29909695/pubmed" id="29909695" target="_blank">29909695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21221000">
<a name="21221000"></a>Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. <i>Crit Care Med</i>. 2011;39(3):560-570. doi:10.1097/CCM.0b013e318206c3b2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21221000/pubmed" id="21221000" target="_blank">21221000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23712701">
<a name="23712701"></a>Bookstaver PB, Bland CM, Qureshi ZP, et al; SERGE-45 Investigators. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. <i>Pharmacotherapy</i>. 2013;33(12):1322-1330. doi:10.1002/phar.1298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23712701/pubmed" id="23712701" target="_blank">23712701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19193593">
<a name="19193593"></a>Bookstaver PB, Williamson JC, Tucker BK, Raad II, Sherertz RJ. Activity of novel antibiotic lock solutions in a model against isolates of catheter-related bloodstream infections. <i>Ann Pharmacother.</i> 2009;43(2):210-219. doi: 10.1345/aph.1L145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19193593/pubmed" id="19193593" target="_blank">19193593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bosak.1">
<a name="Bosak.1"></a>Bosak A, Jivcu C. Daptomycin induced myopathy, eosinophilic interstitial nephritis, and acute eosinophilic pneumonia [abstract]. <i>American Journal of Respiratory and Critical Care Medicine</i>. 2016;193:abstract A1655.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32639465">
<a name="32639465"></a>Bradley JS, Arrieta AC, Digtyar VA, et al. Daptomycin for pediatric gram-positive acute hematogenous osteomyelitis. <i>Pediatr Infect Dis J</i>. 2020;39(9):814-823.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32639465/pubmed" id="32639465" target="_blank">32639465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25361023">
<a name="25361023"></a>Bradley JS, Nelson, JN, Barnett ED, et al, eds. Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age. <i>Pediatr Infect Dis J</i>. 2014;33(9):936-939.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25361023/pubmed" id="25361023" target="_blank">25361023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32010602">
<a name="32010602"></a>Breilh D, Honore PM, De Bels D, et al; IVOIRE study group. Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: lessons learned from an ancillary study of the IVOIRE trial. <i>J Transl Int Med</i>. 2019;7(4):155-169. doi:10.2478/jtim-2019-0031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32010602/pubmed" id="32010602" target="_blank">32010602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28011602">
<a name="28011602"></a>Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients. <i>Clin Infect Dis.</i> 2017;64(5):605-613. doi:10.1093/cid/ciw815.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28011602/pubmed" id="28011602" target="_blank">28011602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24503131">
<a name="24503131"></a>Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by <i>Clostridium difficile</i>. <i>Gastroenterology</i>. 2014;146(6):1547-1553. doi:10.1053/j.gastro.2014.01.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24503131/pubmed" id="24503131" target="_blank">24503131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478961">
<a name="23478961"></a>Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated <i>Clostridium difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2013;57(5):2326-2332. doi:10.1128/AAC.02176-12<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23478961/pubmed" id="23478961" target="_blank">23478961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25465585">
<a name="25465585"></a>Budovich A, Blum S, Berger B. Daptomycin-induced hyperkalemia in a patient with normal renal function. <i>Am J Health Syst Pharm</i>. 2014;71(24):2137-2141. doi:10.2146/ajhp140081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25465585/pubmed" id="25465585" target="_blank">25465585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23208714">
<a name="23208714"></a>Butterfield JM, Mueller BA, Patel N, et al. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. <i>Antimicrob Agents Chemother</i>. 2013;57(2):864-872. doi: 10.1128/AAC.02000-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23208714/pubmed" id="23208714" target="_blank">23208714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29906315">
<a name="29906315"></a>Butterfield-Cowper JM, Lodise TP Jr, Pai MP. A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults. <i>Pharmacotherapy</i>. 2018;38(9):981-985. doi:10.1002/phar.2157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29906315/pubmed" id="29906315" target="_blank">29906315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24080644">
<a name="24080644"></a>Carugati M, Bayer AS, Miró JM, et al; International Collaboration on Endocarditis. High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the International Collaboration on Endocarditis. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6213-6222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24080644/pubmed" id="24080644" target="_blank">24080644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23774437">
<a name="23774437"></a>Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. <i>Antimicrob Agents Chemother</i>. 2013;57(9):4190-4196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23774437/pubmed" id="23774437" target="_blank">23774437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25477584">
<a name="25477584"></a>Caulder CR, Sloan A, Yasir A, Bookstaver PB. Infusion-related reaction following daptomycin two-minute rapid intravenous administration. <i>Hosp Pharm</i>. 2014;49(7):644-646. doi:10.1310/hpj4907-644<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25477584/pubmed" id="25477584" target="_blank">25477584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention. FAQs for clinicians about <i>C. diff</i>. Updated July 20, 2021. Accessed December 3, 2021. <a href="https://www.cdc.gov/cdiff/clinicians/faq.html" target="_blank">https://www.cdc.gov/cdiff/clinicians/faq.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chan.1">
<a name="Chan.1"></a>Chan S, Klein JD, Kishel JJ, Donovan BJ. Linezolid- and vancomycin-resistant <i>Enterococcus Faecium</i> peritonitis and bacteremia successfully treated with daptomycin in an immunocompromised pediatric patient with hepatic and renal failure. <i>Infect Dis Clin Pract</i>. 2012;20(2):154-156.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24030545">
<a name="24030545"></a>Chaves RL, Chakraborty A, Benziger D, Tannenbaum S. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. <i>J Antimicrob Chemother</i>. 2014;69(1):200-210. doi:10.1093/jac/dkt342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24030545/pubmed" id="24030545" target="_blank">24030545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chu.1">
<a name="Chu.1"></a>Chu VH. Antimicrobial therapy of left-sided native valve endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29374204">
<a name="29374204"></a>Chuang YC, Chen PY, Lin CY, Chen YC, Wang JT, Chang SC. A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections. <i>Sci Rep.</i> 2018;8(1):1632. doi: 10.1038/s41598-018-19986-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29374204/pubmed" id="29374204" target="_blank">29374204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28329222">
<a name="28329222"></a>Chuang YC, Lin HY, Chen PY, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. <i>Clin Infect Dis.</i> 2017;64(8):1026-1034. doi: 10.1093/cid/cix024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28329222/pubmed" id="28329222" target="_blank">28329222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35639586">
<a name="35639586"></a>Chuang YC, Lin HY, Yang JL, et al. Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin. <i>J Antimicrob Chemother</i>. 2022;77(8):2278-2287. doi:10.1093/jac/dkac164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/35639586/pubmed" id="35639586" target="_blank">35639586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17124423">
<a name="17124423"></a>Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. <i>Blood Purif</i>. 2006;24(5-6):548-554. doi:10.1159/000097078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/17124423/pubmed" id="17124423" target="_blank">17124423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18309318">
<a name="18309318"></a>Cohen-Wolkowiez M, Smith PB, Benjamin DK Jr, et al, "Daptomycin Use in Infants: Report of Two Cases With Peak and Trough Drug Concentrations," <i>J Perinatol</i>, 2008, 28(3):233-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18309318/pubmed" id="18309318" target="_blank">18309318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22627869">
<a name="22627869"></a>Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr, Smith PB. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. <i>Pediatr Infect Dis J</i>. 2012;31(9):935-937.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22627869/pubmed" id="22627869" target="_blank">22627869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24755188">
<a name="24755188"></a>Collins CE, Ayturk MD, Flahive JM, Emhoff TA, Anderson FA Jr, Santry HP. Epidemiology and outcomes of community-acquired <i>Clostridium difficile</i> infections in Medicare beneficiaries. <i>J Am Coll Surg</i>. 2014;218(6):1141-1147.e1. doi:10.1016/j.jamcollsurg.2014.01.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24755188/pubmed" id="24755188" target="_blank">24755188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21965434">
<a name="21965434"></a>Colomba C, Rubino R, Siracusa L, Mazzola G, Titone L. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C. <i>J Antimicrob Chemother</i>. 2012;67(1):249-250. doi:10.1093/jac/dkr398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21965434/pubmed" id="21965434" target="_blank">21965434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22511636">
<a name="22511636"></a>Corona Pérez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D, et al. Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. <i>J Antimicrob Chemother</i>. 2012;67(7):1749-1754. doi:10.1093/jac/dks119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22511636/pubmed" id="22511636" target="_blank">22511636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29508663">
<a name="29508663"></a>Cortes-Penfield N, Oliver NT, Hunter A, Rodriguez-Barradas M. Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia.<i> Infect Dis (Lond).</i> 2018;50(8):643-647. doi:10.1080/23744235.2018.1448110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29508663/pubmed" id="29508663" target="_blank">29508663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24051895">
<a name="24051895"></a>Corti N, Rudiger A, Chiesa A, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. <i>Chemotherapy</i>. 2013;59(2):143-151. doi:10.1159/000353400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24051895/pubmed" id="24051895" target="_blank">24051895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cubicin.3">
<a name="Cubicin.3"></a>Cubicin (daptomycin) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme Corp; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cubicin.1">
<a name="Cubicin.1"></a>Cubicin (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cubicin.2">
<a name="Cubicin.2"></a>Cubicin (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CubicinRF.1">
<a name="CubicinRF.1"></a>Cubicin RF (daptomycin) [prescribing information]. Rahway, NJ: Merck Sharp &amp; Dohme LLC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CubicinRF.2">
<a name="CubicinRF.2"></a>Cubicin RF (daptomycin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Accord.1">
<a name="Accord.1"></a>Daptomycin [prescribing information]. Durham, NC: Accord Healthcare, Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Daptomycin [prescribing information]. Lake Forest, IL: Hospira Inc; received August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Daptomycin [prescribing information]. Lake Zurich, IL: Fresenius Kabi; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sagent.1">
<a name="Sagent.1"></a>Daptomycin [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Daptomycin in sodium chloride [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29668884">
<a name="29668884"></a>Dare RK, Tewell C, Harris B, et al. Effect of statin coadministration on the risk of daptomycin-associated myopathy. <i>Clin Infect Dis</i>. 2018;67(9):1356-1363. doi:10.1093/cid/ciy287<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29668884/pubmed" id="29668884" target="_blank">29668884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21327445">
<a name="21327445"></a>Das I, Saluja T, Steeds R. Use of daptomycin in complicated cases of infective endocarditis. <i>Eur J Clin Microbiol Infect Dis</i>. 2011;30(6):807-812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21327445/pubmed" id="21327445" target="_blank">21327445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22340450">
<a name="22340450"></a>Del Pozo JL, Rodil R, Aguinaga A, et al. Daptomycin lock therapy for gram-positive long-term catheter-related bloodstream infections.<i> Int J Clin Pract.</i> 2012;66(3):305-308. doi: 10.1111/j.1742-1241.2011.02830.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22340450/pubmed" id="22340450" target="_blank">22340450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24994724">
<a name="24994724"></a>Denetclaw TH, Suehiro I, Wang PK, Tolliver GL. Successful treatment of ventriculostomy-associated meningitis caused by multidrug resistant coagulase-negative Staphylococcus epidermidis using low-volume intrathecal daptomycin and loading strategy. <i>Ann Pharmacother</i>. 2014;48(10):1376-1379. doi: 10.1177/1060028014542634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24994724/pubmed" id="24994724" target="_blank">24994724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21690622">
<a name="21690622"></a>Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. <i>Clin Infect Dis.</i> 2011;53(2):158-163. doi: 10.1093/cid/cir340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21690622/pubmed" id="21690622" target="_blank">21690622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23891432">
<a name="23891432"></a>Di Paolo A, Tascini C, Polillo M, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. <i>Int J Antimicrob Agents.</i> 2013;42(3):250-255. doi:10.1016/j.ijantimicag.2013.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23891432/pubmed" id="23891432" target="_blank">23891432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23190763">
<a name="23190763"></a>Dohmen PM, Guleri A, Capone A, et al. Daptomycin for the treatment of infective endocarditis: results from a European registry. <i>J Antimicrob Chemother</i>. 2013;68(4):936-942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23190763/pubmed" id="23190763" target="_blank">23190763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27259674">
<a name="27259674"></a>Durante-Mangoni E, Andini R, Parrella A, et al. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. <i>Int J Antimicrob Agents</i>. 2016;48(1):61-68. doi:10.1016/j.ijantimicag.2016.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/27259674/pubmed" id="27259674" target="_blank">27259674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12654665">
<a name="12654665"></a>Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. <i>Antimicrob Agents Chemother</i>. 2003;47(4):1318-1323. doi:10.1128/AAC.47.4.1318-1323.2003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/12654665/pubmed" id="12654665" target="_blank">12654665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15601805">
<a name="15601805"></a>Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. <i>J Clin Pharmacol</i>. 2005;45(1):48-56. doi:10.1177/0091270004269562.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/15601805/pubmed" id="15601805" target="_blank">15601805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18156605">
<a name="18156605"></a>Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by <i>Enterococcus faecalis</i> with intraventricular daptomycin. <i>J Antimicrob Chemother</i>. 2008;61(2):461-462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18156605/pubmed" id="18156605" target="_blank">18156605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22649456">
<a name="22649456"></a>Erritouni M, Ktaich N, Rahal JJ, et al. Use of daptomycin for the treatment of methicillin-resistant coagulase-negative Staphylococcal ventriculitis. <i>Case Rep Med</i>. 2012;2012:593578. doi: 10.1155/2012/593578.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22649456/pubmed" id="22649456" target="_blank">22649456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23403427">
<a name="23403427"></a>Estes R, Theusch J, Beck A, Pitrak D, Mullane KM. Activity of daptomycin with or without 25 percent ethanol compared to combinations of minocycline, EDTA, and 25 percent ethanol against methicillin-resistant Staphylococcus aureus isolates embedded in biofilm. <i>Antimicrob Agents Chemother.</i> 2013;57(4):1998-2000. doi: 10.1128/AAC.01129-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23403427/pubmed" id="23403427" target="_blank">23403427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23361566">
<a name="23361566"></a>Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? <i>J Infect Chemother</i>. 2013a;19(4):732-739. doi:10.1007/s10156-013-0559-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23361566/pubmed" id="23361566" target="_blank">23361566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24046298">
<a name="24046298"></a>Falcone M, Russo A, Venditti M, Novelli A, Pai MP. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. <i>Clin Infect Dis</i>. 2013b;57(11):1568-1576. doi:10.1093/cid/cit582<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24046298/pubmed" id="24046298" target="_blank">24046298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16914701">
<a name="16914701"></a>Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by <i>Staphylococcus aureus</i>. <i>N Engl J Med</i>. 2006;355(7):653-665. doi:10.1056/NEJMoa053783<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/16914701/pubmed" id="16914701" target="_blank">16914701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30728962">
<a name="30728962"></a>Fox AN, Smith WJ, Kupiec KE, et al. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight [published online January 30, 2019]. <i>Ther Adv Infect Dis</i>. doi:10.1177/2049936118820230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30728962/pubmed" id="30728962" target="_blank">30728962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26910590">
<a name="26910590"></a>Garazzino S, Castagnola E, Di Gangi M, et al. Daptomycin for children in clinical practice experience. <i>Pediatr Infect Dis J</i>. 2016;35(6):639-641.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26910590/pubmed" id="26910590" target="_blank">26910590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25859172">
<a name="25859172"></a>Gawronski KM. Successful use of daptomycin in a preterm neonate with persistent methicillin-resistant Staphylococcus epidermidis bacteremia. <i>J Pediatr Pharmacol Ther</i>. 2015;20(1):61-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25859172/pubmed" id="25859172" target="_blank">25859172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30858203">
<a name="30858203"></a>Geriak M, Haddad F, Rizvi K, et al. Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. <i>Antimicrob Agents Chemother.</i> 2019;63(5):e02483-18. doi: 10.1128/AAC.02483-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30858203/pubmed" id="30858203" target="_blank">30858203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Girand.1">
<a name="Girand.1"></a>Girand HL. Antibiotic lock therapy for treatment of catheter-related bloodstream infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 4, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27228997">
<a name="27228997"></a>Gisler V, Müller S, Müller L, Jörg-Walther L, Sendi P. Acute angioedema triggered by daptomycin. <i>Infect Dis Ther</i>. 2016;5(2):201-205. doi:10.1007/s40121-016-0111-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/27228997/pubmed" id="27228997" target="_blank">27228997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.1">
<a name="Goldenberg.1"></a>Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24999649">
<a name="24999649"></a>Gordon Spratt EA, Schmidt AN, Kantrow SM. Daptomycin-induced acute generalized exanthematous pustulosis. <i>Cutis</i>. 2014;93(6):E10-E12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24999649/pubmed" id="24999649" target="_blank">24999649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother.</i> 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30295740">
<a name="30295740"></a>Grégoire N, Marchand S, Ferrandière M, et al. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. <i>J Antimicrob Chemother</i>. 2019;74(1):117-125. doi:10.1093/jac/dky374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30295740/pubmed" id="30295740" target="_blank">30295740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320109">
<a name="26320109"></a>Habib G, Lancellotti P, Antunes MJ, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).<i> Eur Heart J.</i> 2015;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26320109/pubmed" id="26320109" target="_blank">26320109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25758082">
<a name="25758082"></a>Hagiya H, Hasegawa K, Asano K, et al. Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin. <i>Intern Med</i>. 2015;54(5):525-529. doi:10.2169/internalmedicine.54.3397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25758082/pubmed" id="25758082" target="_blank">25758082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24583445">
<a name="24583445"></a>Hagiya H, Kimura M, Miyamoto T, Haruki Y, Otsuka F. Acute generalized exanthematous pustulosis caused by daptomycin in a critically ill burn victim. <i>Intern Med</i>. 2014;53(5):511-514. doi:10.2169/internalmedicine.53.0679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24583445/pubmed" id="24583445" target="_blank">24583445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30430398">
<a name="30430398"></a>Hagiya H, Kokado R, Okuno H, Tomono K. Daptomycin-associated myopathy induced by concomitant administration of mirabegron. <i>Infection</i>. 2019;47(2):331-332. doi:10.1007/s15010-018-1252-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30430398/pubmed" id="30430398" target="_blank">30430398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1659305">
<a name="1659305"></a>Hanberger H, Nilsson LE, Maller R, Isaksson B. Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. <i>Antimicrob Agents Chemother.</i> 1991;35(9):1710-1716. doi:10.1128/aac.35.9.1710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/1659305/pubmed" id="1659305" target="_blank">1659305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hasbun.1">
<a name="Hasbun.1"></a>Hasbun R. Treatment of bacterial meningitis caused by specific pathogens in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259698">
<a name="24259698"></a>Haselden M, Leach M, Bohm N. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. <i>Ann Pharmacother.</i> 2013;47(10):1342-1347. doi:10.1177/1060028013503110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24259698/pubmed" id="24259698" target="_blank">24259698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis. <i>Pharmacotherapy. </i>2009;29(5):562-577.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22146873">
<a name="22146873"></a>Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for <i>Clostridium difficile</i> infection after exposure to antibiotics. <i>J Antimicrob Chemother</i>. 2012;67(3):742-748. doi:10.1093/jac/dkr508<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22146873/pubmed" id="22146873" target="_blank">22146873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29093391">
<a name="29093391"></a>Higashi Y, Nakamura S, Tsuji Y, et al. Daptomycin-induced eosinophilic pneumonia and a review of the published literature. <i>Intern Med</i>. 2018;57(2):253-258. doi:10.2169/internalmedicine.9010-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29093391/pubmed" id="29093391" target="_blank">29093391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28003110">
<a name="28003110"></a>Hirai J, Hagihara M, Haranaga S, et al. Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature. <i>J Infect Chemother</i>. 2017;23(4):245-249. doi:10.1016/j.jiac.2016.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28003110/pubmed" id="28003110" target="_blank">28003110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598098">
<a name="26598098"></a>Hobbs AL, Shea KM, Roberts KM, Daley MJ. Implications of augmented renal clearance on drug dosing in critically ill patients: a focus on antibiotics. <i>Pharmacotherapy</i>. 2015;35(11):1063-1075. doi:10.1002/phar.1653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26598098/pubmed" id="26598098" target="_blank">26598098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21127158">
<a name="21127158"></a>Hussain A, Kairamkonda V, Jenkins DR. Successful treatment of methicillin-resistant <i>Staphylococcus aureus</i> bacteraemia in a neonate using daptomycin. <i>J Med Microbiol</i>. 2011;60(pt 3):381-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21127158/pubmed" id="21127158" target="_blank">21127158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). Storage and reconstitution differ for Cubicin and Cubicin RF by Merck. <i>ISMP Medication Safety Alert</i>. October 6, 2016. Available at https://www.ismp.org/acute-care/october-6-2016
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25548523">
<a name="25548523"></a>Justo JA, Bookstaver PB. Antibiotic lock therapy: review of technique and logistical challenges.<i> Infect Drug Resist.</i> 2014;7:343-363. doi: 10.2147/IDR.S51388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25548523/pubmed" id="25548523" target="_blank">25548523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Karchmer.1">
<a name="Karchmer.1"></a>Karchmer AW, Chu VH. Antimicrobial therapy of prosthetic valve endocarditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 29, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23299359">
<a name="23299359"></a>Kaya S, Yilmaz G, Kalkan A, Ertunç B, Köksal I. Treatment of gram-positive left-sided infective endocarditis with daptomycin. <i>J Infect Chemother</i>. 2013;19(4):698-702.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23299359/pubmed" id="23299359" target="_blank">23299359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16410267">
<a name="16410267"></a>Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. <i>J Antimicrob Chemother</i>. 2006;57(3):578-579. doi:10.1093/jac/dki476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/16410267/pubmed" id="16410267" target="_blank">16410267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30012755">
<a name="30012755"></a>Kidd JM, Abdelraouf K, Asempa TE, Humphries RM, Nicolau DP. Pharmacodynamics of daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model. <i>Antimicrob Agents Chemother.</i> 2018;62(10):e00506-18. doi:10.1128/AAC.00506-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30012755/pubmed" id="30012755" target="_blank">30012755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30689699">
<a name="30689699"></a>Kido K, Oyen AA, Beckmann MA, Brouse SD. Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy. <i>Am J Health Syst Pharm</i>. 2019;76(4):206-210. doi:10.1093/ajhp/zxy036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30689699/pubmed" id="30689699" target="_blank">30689699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20031929">
<a name="20031929"></a>Kielstein JT, Eugbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. <i>Nephrol Dial Transplant.</i> 2010;25(5):1537-1541. doi:10.1093/ndt/gfp704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20031929/pubmed" id="20031929" target="_blank">20031929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22612850">
<a name="22612850"></a>Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. <i>Drug Saf</i>. 2012;35(6):447-457. doi:10.2165/11597460-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22612850/pubmed" id="22612850" target="_blank">22612850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24801642">
<a name="24801642"></a>King ST, Walker ED, Cannon CG, Finley RW. Daptomycin-induced rhabdomyolysis and acute liver injury. <i>Scand J Infect Dis</i>. 2014;46(7):537-540. doi:10.3109/00365548.2014.901555<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24801642/pubmed" id="24801642" target="_blank">24801642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23325425">
<a name="23325425"></a>Knoll BM, Spieler PJ, Kubiak DW, et al. Neutropenia Associated With Prolonged Daptomycin Use. <i>Clin Infect Dis.</i> 2013;56(9):1353-1354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23325425/pubmed" id="23325425" target="_blank">23325425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397557">
<a name="30397557"></a>Kumar S, Acosta-Sanchez I, Rajagopalan N. Daptomycin-induced acute eosinophilic pneumonia. <i>Cureus</i>. 2018;10(6):e2899. doi:10.7759/cureus.2899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30397557/pubmed" id="30397557" target="_blank">30397557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18636964">
<a name="18636964"></a>Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. <i>Clin Infect Dis.</i> 2008;47(4):588-590. doi: 10.1086/590257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18636964/pubmed" id="18636964" target="_blank">18636964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22346259">
<a name="22346259"></a>Leng TY, Aan MK, Chan M, Tsien LT. Acute generalized exanthematous pustulosis caused by daptomycin. <i>Ann Dermatol</i>. 2011;23(suppl 3):S288-S289. doi:10.5021/ad.2011.23.S3.S288<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22346259/pubmed" id="22346259" target="_blank">22346259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33603575">
<a name="33603575"></a>Lim SY, Lewis T, Woo S, et al. Daptomycin pharmacokinetics in adolescents undergoing hemodialysis and peritoneal dialysis: a case series with pharmacokinetic modeling. <i>J Pediatr Pharmacol Ther</i>. 2021;26(2):123-132. doi:10.5863/1551-6776-26.2.123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/33603575/pubmed" id="33603575" target="_blank">33603575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15659542">
<a name="15659542"></a>Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. <i>J Antimicrob Chemother</i>. 2005;55(2):240-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/15659542/pubmed" id="15659542" target="_blank">15659542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis.</i> 2011;52(3):285-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31625394">
<a name="31625394"></a>Lorenzo MP, Housman EL, Housman ST. Evaluation of fixed-dose daptomycin in obese patients with bloodstream infections caused by <i>Staphylococcus aureus</i>. <i>Ann Pharmacother</i>. 2020;54(3):290-291. doi:10.1177/1060028019883810.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/31625394/pubmed" id="31625394" target="_blank">31625394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11181370">
<a name="11181370"></a>Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. <i>Antimicrob Agents Chemother.</i> 2001;45(3):845-851. doi:10.1128/AAC.45.3.845-851.2001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/11181370/pubmed" id="11181370" target="_blank">11181370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lowy.1">
<a name="Lowy.1"></a>Lowy FD. Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6. 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lowy.2">
<a name="Lowy.2"></a>Lowy FD. Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6. 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26563898">
<a name="26563898"></a>Malizos K, Sarma J, Seaton RA, et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. <i>Eur J Clin Microbiol Infect Dis.</i> 2016;35(1):111-118. doi: 10.1007/s10096-015-2515-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26563898/pubmed" id="26563898" target="_blank">26563898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28869666">
<a name="28869666"></a>Meng L, Mui E, Holubar MK, Deresinski SC. Comprehensive guidance for antibiotic dosing in obese adults [published correction appears in <i>Pharmacotherapy</i>. 2018;38(2):302]. <i>Pharmacotherapy</i>. 2017;37(11):1415-1431. doi: 10.1002/phar.2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28869666/pubmed" id="28869666" target="_blank">28869666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in <i>Clin Infect Dis.</i> 2010;50(7):1079; <i>Clin Infect Dis.</i> 2010;50(3):457]. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi: 10.1086/599376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18254489">
<a name="18254489"></a>Metz GM, Thyagarajan A. A successful protocol for daptomycin desensitization. <i>Ann Allergy Asthma Immunol</i>. 2008;100(1):87. doi:10.1016/S1081-1206(10)60411-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/18254489/pubmed" id="18254489" target="_blank">18254489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24798278">
<a name="24798278"></a>Montange D, Berthier F, Leclerc G, et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. <i>Antimicrob Agents Chemother.</i> 2014;58(7):3991-3996. doi:10.1128/AAC.02344-14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24798278/pubmed" id="24798278" target="_blank">24798278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28943826">
<a name="28943826"></a>Morris S, Gould K, Ferguson LP. The use of daptomycin to treat methicillin-resistant <i>Staphylococcus epidermidis</i> bacteremia in a critically ill child with renal failure. <i>J Pediatr Pharmacol Ther</i>. 2017;22(4):300-303. doi:10.5863/1551-6776-22.4.300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28943826/pubmed" id="28943826" target="_blank">28943826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23232018">
<a name="23232018"></a>Mueller SW, Kiser TH, Anderson TA, Neumann RT. Intraventricular daptomycin and intravenous linezolid for the treatment of external ventricular-drain-associated ventriculitis due to vancomycin-resistant Enterococcus faecium. <i>Ann Pharmacother.</i> 2012;46(12):e35. doi: 10.1345/aph.1R412.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23232018/pubmed" id="23232018" target="_blank">23232018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murray.1">
<a name="Murray.1"></a>Murray BE, Miller WR. Treatment of enterococcal infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed December 3, 2021. https://www.nice.org.uk/guidance/cg183
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NCT00711802.1">
<a name="NCT00711802.1"></a>NCT00711802, “Safety and Efficacy Study of Daptomycin in Pediatric Subjects (2-17 Years) With Skin and Skin Structure Infections,” Unpublished data. Available at <a href="https://clinicaltrials.gov/ct2/show/NCT00711802?term=NCT+00711802&amp;amp;rank=1%20" target="_blank">http://clinicaltrials.gov/ct2/show/NCT00711802?term=NCT+00711802&amp;rank=1 </a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913322">
<a name="30913322"></a>Nellore A, Huprikar S; AST ID Community of Practice. Vancomycin-resistant enterococcus in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13549. doi: 10.1111/ctr.13549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30913322/pubmed" id="30913322" target="_blank">30913322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28406091">
<a name="28406091"></a>Nickerson M, Bhargava A, Kale-Pradhan PB. Daptomycin-associated eosinophilic pneumonia with rechallenge: a case report. <i>Int J Clin Pharmacol Ther</i>. 2017;55(6):521-524. doi:10.5414/CP202952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28406091/pubmed" id="28406091" target="_blank">28406091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3036501">
<a name="3036501"></a>Nord CE, Lindmark A, Persson I. Susceptibility of <i>Clostridium difficile</i> to LY146032. <i>Eur J Clin Microbiol</i>. 1987;6(2):189. doi:10.1007/BF02018207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/3036501/pubmed" id="3036501" target="_blank">3036501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19732094">
<a name="19732094"></a>Norén T, Alriksson I, Akerlund T, Burman LG, Unemo M. In vitro susceptibility to 17 antimicrobials of clinical <i>Clostridium difficile</i> isolates collected in 1993-2007 in Sweden. <i>Clin Microbiol Infect</i>. 2010;16(8):1104-1110. doi:10.1111/j.1469-0691.2009.03048.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19732094/pubmed" id="19732094" target="_blank">19732094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30423035">
<a name="30423035"></a>Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. <i>Clin Infect Dis</i>. 2019;68(1):e1-e35. doi:10.1093/cid/ciy745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30423035/pubmed" id="30423035" target="_blank">30423035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19346518">
<a name="19346518"></a>Odero RO, Cleveland KO, Gelfand MS. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. <i>J Antimicrob Chemother</i>. 2009;63(6):1299-1300. doi:10.1093/jac/dkp127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/19346518/pubmed" id="19346518" target="_blank">19346518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11036005">
<a name="11036005"></a>Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. <i>Antimicrob Agents Chemother</i>. 2000;44(11):2948-2953. doi:10.1128/AAC.44.11.2948-2953.2000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/11036005/pubmed" id="11036005" target="_blank">11036005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24831000">
<a name="24831000"></a>Ortega R, Salmerón-García A, Cabeza J, Capitán-Vallvey LF, Navas N. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20°C. <i>Am J Health Syst Pharm.</i> 2014;71(11):956-959. doi: 10.2146/ajhp130481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24831000/pubmed" id="24831000" target="_blank">24831000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osmon.1">
<a name="Osmon.1"></a>Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17548489">
<a name="17548489"></a>Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. <i>Antimicrob Agents Chemother</i>. 2007;51(8):2741-2747. doi:10.1128/AAC.00059-07.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/17548489/pubmed" id="17548489" target="_blank">17548489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12937016">
<a name="12937016"></a>Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.<i> Antimicrob Agents Chemother.</i> 2003;47(9):3012-3014. doi:10.1128/aac.47.9.3012-3014.2003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/12937016/pubmed" id="12937016" target="_blank">12937016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16705566">
<a name="16705566"></a>Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. <i>Clin Infect Dis</i>. 2006;42(12):e108-e110. doi:10.1086/504379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/16705566/pubmed" id="16705566" target="_blank">16705566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21282429">
<a name="21282429"></a>Patel N, Cardone K, Grabe DW, et al. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.<i> Antimicrob Agents Chemother.</i> 2011;55(4):1677-1683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/21282429/pubmed" id="21282429" target="_blank">21282429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30607829">
<a name="30607829"></a>Piva S, Di Paolo A, Galeotti L, et al. Daptomycin plasma and CSF levels in patients with healthcare-associated meningitis.<i> Neurocrit Care</i>. 2019;31(1):116-124. doi:10.1007/s12028-018-0657-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/30607829/pubmed" id="30607829" target="_blank">30607829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25406298">
<a name="25406298"></a>Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. <i>J Antimicrob Chemother</i>. 2015;70(3):643-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25406298/pubmed" id="25406298" target="_blank">25406298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32725216">
<a name="32725216"></a>Pujol M, Miró JM, Shaw E, et al; MRSA Bacteremia (BACSARM) Trial Investigators. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. <i>Clin Infect Dis</i>. 2021;72(9):1517-1525. doi:10.1093/cid/ciaa1081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32725216/pubmed" id="32725216" target="_blank">32725216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29225987">
<a name="29225987"></a>Rachid M, Ahmad K, Saunders-Kurban M, Fatima A, Shah A, Nahhas A. Daptomycin-induced acute eosinophilic pneumonia: late onset and quick recovery. <i>Case Rep Pulmonol</i>. 2017;2017:8525789. doi:10.1155/2017/8525789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29225987/pubmed" id="29225987" target="_blank">29225987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33889339">
<a name="33889339"></a>Raman V, Chaudhary I, Shieh S. Eosinophilic pneumonia: a case of daptomycin induced lung injury. <i>J Community Hosp Intern Med Perspect</i>. 2021;11(2):280-285. doi:10.1080/20009666.2021.1883813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/33889339/pubmed" id="33889339" target="_blank">33889339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28366221">
<a name="28366221"></a>Ross JJ. Septic arthritis of native joints. <i>Infect Dis Clin North Am.</i> 2017;31(2):203-218. doi: 10.1016/j.idc.2017.01.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28366221/pubmed" id="28366221" target="_blank">28366221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693519">
<a name="14693519"></a>Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. <i>Antimicrob Agents Chemother</i>. 2004;48(1):63-68. doi:10.1128/aac.48.1.63-68.2004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/14693519/pubmed" id="14693519" target="_blank">14693519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25017183">
<a name="25017183"></a>Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. <i>Clin Ther.</i> 2014;36(10):1317-1333. doi: 10.1016/j.clinthera.2014.05.061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/25017183/pubmed" id="25017183" target="_blank">25017183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20007981">
<a name="20007981"></a>Salama NN, Segal JH, Churchwell MD, et al. Single-Dose Daptomycin Pharmacokinetics in Chronic Haemodialysis Patients. <i>Nephrol Dial Transplant.</i> 2010;25(4):1279-1284.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20007981/pubmed" id="20007981" target="_blank">20007981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20013573">
<a name="20013573"></a>Sarafidis K, Iosifidis E, Gikas E, Tsivitanidou M, Drossou-Agakidou V, Roilides E. Daptomycin use in a neonate: serum level monitoring and outcome. <i>Am J Perinatol</i>. 2010;27(5):421-424. Erratum in <i>Am J Perinatol</i>. 2012;29(10):843.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20013573/pubmed" id="20013573" target="_blank">20013573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.1">
<a name="Sexton.1"></a>Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2">
<a name="Sexton.2"></a>Sexton DJ, Sampson JH. Spinal epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29053792">
<a name="29053792"></a>Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. <i>Clin Infect Dis</i>. 2017;65(12):e45-e80. doi:10.1093/cid/cix669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29053792/pubmed" id="29053792" target="_blank">29053792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15898002">
<a name="15898002"></a>Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. <i>J Infect Dis.</i> 2005;191(12):2149-2152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/15898002/pubmed" id="15898002" target="_blank">15898002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33923382">
<a name="33923382"></a>Soldevila-Boixader L, Villanueva B, Ulldemolins M, et al. Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection. <i>Antibiotics (Basel)</i>. 2021;10(4):446. doi:10.3390/antibiotics10040446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/33923382/pubmed" id="33923382" target="_blank">33923382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Southwick.1">
<a name="Southwick.1"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stevens.1">
<a name="Stevens.1"></a>Stevens DL, Baddour LM. Necrotizing soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis.</i> 2015;60(9):1448]. <i>Clin Infect Dis.</i> 2014;59(2):e10-e52. doi: 10.1093/cid/ciu444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28471867">
<a name="28471867"></a>Syrogiannopoulos GA, Michoula AN, Petinaki E, Grivea IN. Daptomycin use in children: experience with various types of infection and age groups. <i>Pediatr Infect Dis J</i>. 2017;36(10):962-966. doi:10.1097/INF.0000000000001629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28471867/pubmed" id="28471867" target="_blank">28471867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29559785">
<a name="29559785"></a>Tai CH, Shao CH, Chen CY, Lin SW, Wu CC. Safety of high-dose daptomycin in patients with severe renal impairment. <i>Ther Clin Risk Manag</i>. 2018;14:493-499. doi:10.2147/TCRM.S159587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29559785/pubmed" id="29559785" target="_blank">29559785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26484430">
<a name="26484430"></a>Tedeschi S, Tumietto F, Conti M, Giannella M, Viale P, S. Orsola Antimicrobial Stewardship Team. Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections.<i> Pediatr Infect Dis J</i>. 2016;35(2):180-182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/26484430/pubmed" id="26484430" target="_blank">26484430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31673242">
<a name="31673242"></a>Teng C, Baus C, Wilson JP, Frei CR. Rhabdomyolysis associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). <i>Int J Med Sci</i>. 2019;16(11):1504-1509. doi:10.7150/ijms.38605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/31673242/pubmed" id="31673242" target="_blank">31673242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29235661">
<a name="29235661"></a>Timbrook TT, Caffrey AR, Luther MK, Lopes V, LaPlante KL. Association of higher daptomycin dose (7 mg/kg or greater) with improved survival in patients with methicillin-resistant Staphylococcus aureus bacteremia. <i>Pharmacotherapy</i>. 2018;38(2):189-196. doi: 10.1002/phar.2070.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29235661/pubmed" id="29235661" target="_blank">29235661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20375031">
<a name="20375031"></a>Traunmüller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. <i>J Antimicrob Chemother.</i> 2010;65(6):1252-1257. doi:10.1093/jac/dkq109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20375031/pubmed" id="20375031" target="_blank">20375031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tufariello.1">
<a name="Tufariello.1"></a>Tufariello JM, Lowy FD. Infection due to coagulase-negative staphylococci: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tunkel.1">
<a name="Tunkel.1"></a>Tunkel AR. Treatment of bacterial meningitis caused by specific pathogens in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis</i>. 2017;64(6):e34-e65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16870765">
<a name="16870765"></a>Tyrrell KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ. In vitro activities of daptomycin, vancomycin, and penicillin against <i>Clostridium difficile</i>, <i>C. perfringens</i>, <i>Finegoldia magna</i>, and <i>Propionibacterium acnes</i>. <i>Antimicrob Agents Chemother</i>. 2006;50(8):2728-2731. doi:10.1128/AAC.00357-06<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/16870765/pubmed" id="16870765" target="_blank">16870765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999664">
<a name="27999664"></a>Uppal P, LaPlante KL, Gaitanis MM, Jankowich MD, Ward KE. Daptomycin-induced eosinophilic pneumonia - a systematic review. <i>Antimicrob Resist Infect Control</i>. 2016;5:55. doi:10.1186/s13756-016-0158-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/27999664/pubmed" id="27999664" target="_blank">27999664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27216385">
<a name="27216385"></a>Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. <i>Clostridium difficile</i> infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. <i>Int J Antimicrob Agents</i>. 2016;48(1):1-10. doi:10.1016/j.ijantimicag.2016.03.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/27216385/pubmed" id="27216385" target="_blank">27216385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20890189">
<a name="20890189"></a>Vilay MA, Grio M, DePestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis [published correction appears in <i>Crit Care Med</i>. 2011;39(5):1247]. <i>Crit Care Med</i>, 2011, 39(1):19-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/20890189/pubmed" id="20890189" target="_blank">20890189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29383748">
<a name="29383748"></a>Villaverde Piñeiro L, Rabuñal Rey R, García Sabina A, Monte Secades R, García Pais MJ. Paralysis of the external popliteal sciatic nerve associated with daptomycin administration. <i>J Clin Pharm Ther</i>. 2018;43(4):578-580. doi:10.1111/jcpt.12666<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29383748/pubmed" id="29383748" target="_blank">29383748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33016513">
<a name="33016513"></a>Vlashyn OO, Lorenz AM, Sobhanie MM, Smith JM, Bond M, Wardlow L. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. <i>J Clin Pharm Ther</i>. 2021;46(2):363-368. doi:10.1111/jcpt.13289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/33016513/pubmed" id="33016513" target="_blank">33016513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29272341">
<a name="29272341"></a>Watson T, Hickok J, Fraker S, Korwek K, Poland RE, Septimus E. Evaluating the risk factors for hospital-onset <i>Clostridium difficile</i> infections in a large healthcare system. <i>Clin Infect Dis</i>. 2018;66(12):1957-1959. doi:10.1093/cid/cix1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/29272341/pubmed" id="29272341" target="_blank">29272341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31964789">
<a name="31964789"></a>Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic exposure and risk for hospital-associated <i>Clostridioides difficile</i> infection. <i>Antimicrob Agents Chemother</i>. 2020;64(4):e02169-19. doi:10.1128/AAC.02169-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/31964789/pubmed" id="31964789" target="_blank">31964789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weintrob.1">
<a name="Weintrob.1"></a>Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and Maternal Medication, Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32083673">
<a name="32083673"></a>Xie F, Li S, Cheng Z. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. <i>J Antimicrob Chemother</i>. 2020;75(6):1559-1566. doi:10.1093/jac/dkaa028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32083673/pubmed" id="32083673" target="_blank">32083673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32581153">
<a name="32581153"></a>Yamada T, Ishikawa S, Ishiguro N, Kobayashi M, Iseki K. Evaluation of daptomycin-induced cellular membrane injury in skeletal muscle. <i>Biol Pharm Bull</i>. 2020;43(9):1338-1345. doi:10.1248/bpb.b20-00217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/32581153/pubmed" id="32581153" target="_blank">32581153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34117712">
<a name="34117712"></a>Yamada T, Mitsuboshi S, Suzuki K, Nishihara M, Uchiyama K. Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database. <i>Basic Clin Pharmacol Toxicol</i>. 2021;129(3):268-272. doi:10.1111/bcpt.13618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/34117712/pubmed" id="34117712" target="_blank">34117712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36052120">
<a name="36052120"></a>Ye L, You X, Zhou J, et al. Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment. <i>Front Pharmacol</i>. 2022;13:838599. doi:10.3389/fphar.2022.838599<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/36052120/pubmed" id="36052120" target="_blank">36052120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35146040">
<a name="35146040"></a>Zasowski EJ, Trinh TD, Claeys KC, et al. Multicenter cohort study of ceftaroline versus daptomycin for treatment of methicillin-resistant <i>Staphylococcus aureus</i> bloodstream infection. <i>Open Forum Infect Dis</i>. 2021;9(3):ofab606. doi:10.1093/ofid/ofab606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/daptomycin-drug-information/abstract-text/35146040/pubmed" id="35146040" target="_blank">35146040</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9304 Version 524.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
